Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs Obs Exp SIR 95% CI Exp SIR 95% CI Bladder, Urinary Melanoma of Skin Male 17 16.7 101.5 (59.1-162.5) Male 10 11.0 91.2 (43.7-167.7)Female 5 6.3 79.5 (25.6-185.5)Female 9 8.8 102.5 (46.8-194.7)**Brain and Other Nervous System Multiple Myeloma** Male 8 3.4 234.3 (100.9-461.8)Male 1 2.7 nc (nc-nc) Female 2 2.8 Female 2.1 nc (nc-nc) 1 nc (nc-nc) **Breast** Non-Hodgkin Lymphoma 0 0.5 Male 13 Male (nc-nc) 9.5 136.9 (72.8-234.1)nc Female 63 63.6 99.1 (76.2-126.8) Female 13 8.1 160.8 (85.6-275.1) **Cervix Uteri Oral Cavity & Pharynx** Male 7 6.8 102.9 (41.2-212.1) Female 4 2.7 Female 2 3.1 nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary 101.7 22 21.6 Male (63.7-153.9)27 21.2 Female 127.5 (84.0-185.5) Female 9 6.2 146.0 (66.6-277.1)**Esophagus Pancreas** Male 4 4.5 nc (nc-nc) Male 1 5.3 nc (nc-nc) Female 2 1.2 Female 7 5.6 125.3 (50.2-258.1)nc (nc-nc) **Hodgkin Lymphoma Prostate** 58 90.2 Male 4 1.6 nc (nc-nc) Male 64.3 (68.5-116.6)Female 0 1.2 nc (nc-nc) Kidney & Renal Pelvis Stomach 13 8.9 3 4.1 Male 145.5 (77.4-248.7)Male nc (nc-nc) 8 5.2 Female 1 2.4 Female 153.9 (66.3-303.2)(nc-nc) nc Larynx **Testis** Male 3 2.6 Male 2.5 nc (nc-nc) 1 nc (nc-nc)

• Obs = observed case count; Exp = expected case count;

Female

Male

Male

Male

Female

Female

Lung and Bronchus

Liver and Intrahepatic Bile Ducts

Female

Leukemia

2

6

2

5

2

37

41

0.7

6.0

4.6

4.6

1.6

30.8

31.0

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

nc

99.3

108.3

120.1

132.2

nc

nc

(nc-nc)

(nc-nc)

(nc-nc)

(36.3-216.1)

(34.9-252.8)

(84.6-165.6)

(94.9-179.4)

Thyroid

Male

Female

Uteri Corpus and Uterus, NOS

Female

Male

Female

All Sites / Types

1

11

9

232

238

3.4

10.8

14.3

228.2

220.7

nc

101.8

63.1

101.7

107.8

(nc-nc)

(50.7-182.1)

(28.8-119.8)

(89.0-115.6)

(94.6-122.4)

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

				-	with Standardized incidence				
	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	12	16.1	74.7	(38.5-130.4)	Male	21	12.1	174.0	(107.7-266.0)
Female	6	5.8	104.3	(38.1-227.0)	Female	14	9.9	141.1	(77.1-236.8)
Brain and Other Ne	rvous Sys	<u>tem</u>			Multiple Myeloma				
Male	6	4.0	148.3	(54.2-322.8)	Male	5	2.8	177.4	(57.2-413.9)
Female	3	3.1	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>ma</u>			
Male	0	0.5	nc	(nc-nc)	Male	9	10.3	87.1	(39.8-165.4)
Female	100	72.8	137.4	(111.8-167.2)	Female	8	8.0	100.5	(43.3-198.0)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	3	8.0	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	26	22.4	116.3	(76.0-170.4)					
Female	16	20.0	79.8	(45.6-129.7)	Female	11	6.7	164.0	(81.8-293.5)
Esophagus					<u>Pancreas</u>				
Male	3	4.8	nc	(nc-nc)	Male	9	5.4	167.9	(76.6-318.7)
Female	0	1.1	nc	(nc-nc)	Female	6	5.1	117.9	(43.0-256.6)
Hodgkin Lymphom	<u>a</u>				<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	72	68.4	105.3	(82.4-132.6)
Female	0	1.4	nc	(nc-nc)					
Kidney & Renal Pel	<u>vis</u>				Stomach				
Male	11	10.1	109.3	(54.5-195.7)	Male	3	4.1	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	2.8	nc	(nc-nc)	Male	6	3.1	194.5	(71.0-423.3)
Female	1	0.8	nc	(nc-nc)					, ,
<u>Leukemia</u>					<u>Thyroid</u>				
Male	9	6.4	141.1	(64.4-267.9)	Male	3	4.3	nc	(nc-nc)
Female	7	4.7	150.1	(60.1-309.3)	Female	15	13.7	109.1	(61.0-180.0)
Liver and Intrahepa	tic Bile Du	ucts			Uteri Corpus and Uteri	us, NOS			
Male	4	5.3	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)	Female	15	16.0	94.0	(52.6-155.1)
Lung and Bronchus	<u>s</u>			, ,	All Sites / Types				. ,
Male	_ 12	30.7	39.1	(20.2-68.3)	Male	233	240.6	96.9	(84.8-110.1)
Female	18	29.3	61.5	(36.4-97.2)	Female	247	233.1	106.0	(93.2-120.1)
				,					, ,

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

	<u>Obs</u>	Ехр	SIR	95% CI		<u>Obs</u>	Ехр	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	12.6	103.5	(55.0-177.0)	Male	5	8.0	62.7	(20.2-146.2)
Female	5	4.4	113.8	(36.7-265.5)	Female	2	6.0	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>tem</u>			Multiple Myeloma				
Male	5	2.4	207.3	(66.8-483.8)	Male	2	2.0	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphon	<u>na</u>			
Male	0	0.4	nc	(nc-nc)	Male	5	6.9	72.2	(23.3-168.4)
Female	40	44.5	89.8	(64.1-122.3)	Female	4	5.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	5	4.9	101.4	(32.7-236.6)
Female	0	1.8	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	22	16.0	137.3	(86.0-207.9)					
Female	19	14.5	130.7	(78.6-204.1)	Female	4	4.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	4	3.4	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	68	47.8	142.2	(110.4-180.3)
Female	0	0.8	nc	(nc-nc)					
Kidney & Renal Pelv	<u>/is</u>				<u>Stomach</u>				
Male	7	6.6	106.6	(42.7-219.6)	Male	5	3.0	166.1	(53.5-387.7)
Female	4	3.7	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	5	1.9	260.4	(83.9-607.8)	Male	0	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	4.3	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	7	7.3	95.5	(38.3-196.8)
Liver and Intrahepat	<u>tic Bile Du</u>	<u>icts</u>			Uteri Corpus and Uteru	s, NOS			
Male	4	3.4	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)	Female	6	10.1	59.4	(21.7-129.3)
Lung and Bronchus	<u>i</u>				All Sites / Types				
Male	30	23.3	128.8	(86.9-183.9)	Male	201	168.6	119.2	(103.3-136.9)
Female	15	22.1	67.9	(38.0-112.1)	Female	130	153.7	84.6	(70.7-100.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

	Obs	<u>Ехр</u>	SIR	95% CI	with Standardized incidence	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary	<u> </u>	<u> </u>	<u> </u>	<u> </u>	Melanoma of Skin	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Male	16	12.5	127.7	(73.0-207.5)	Male	5	7.2	69.5	(22.4-162.2)
Female	5	5.0	99.5	(32.1-232.2)	Female	1	5.6	nc	(nc-nc)
Brain and Other Ne	rvous Sys			,	Multiple Myeloma				,
Male	1	2.1	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	0	0.3	nc	(nc-nc)	Male	7	6.4	109.9	(44.0-226.5)
Female	34	42.1	80.7	(55.9-112.7)	Female	7	6.1	115.4	(46.2-237.8)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	3	4.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	23	15.1	152.0	(96.3-228.1)					
Female	17	16.8	101.3	(59.0-162.1)	Female	5	4.2	118.1	(38.1-275.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.1	nc	(nc-nc)	Male	5	3.8	130.3	(42.0-304.0)
Female	2	1.0	nc	(nc-nc)	Female	7	4.5	155.2	(62.2-319.7)
Hodgkin Lymphoma	<u>a</u>				<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	65	43.2	150.3	(116.0-191.6)
Female	0	0.7	nc	(nc-nc)					
Kidney & Renal Pel					<u>Stomach</u>				
Male	7	5.9	119.2	(47.8-245.7)	Male	4	2.9	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	5	4.1	123.2	(39.7-287.4)	Male	0	1.9	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	0	5.9	nc	(nc-nc)
Liver and Intrahepa					Uteri Corpus and Uteru	ıs, NOS			
Male	2	3.0	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)	Female	10	9.5	105.7	(50.6-194.3)
Lung and Bronchus	='				All Sites / Types				
Male	23	22.6	101.7	(64.4-152.6)	Male -	184	156.3	117.7	(101.3-136.0)
Female	35	23.9	146.5	(102.0-203.8)	Female	143	156.5	91.4	(77.0-107.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs 95% CI Obs Exp SIR 95% CI Exp SIR Bladder, Urinary Melanoma of Skin 27 34.9 77.5 (51.0-112.7)20 21.5 93.0 Male (56.8-143.6)15 Female 14.7 102.0 (57.1-168.3)Female 12 17.9 66.9 (34.5-116.8)**Brain and Other Nervous System Multiple Myeloma** 10 155.5 3 5.5 Male 6.4 (74.5-286.0)Male nc (nc-nc) 9 5 5.6 160.1 (73.1-303.9)Female 4.8 104.6 (33.7-244.1)Female Non-Hodgkin Lymphoma **Breast** 0 1.0 12 18.9 63.5 (32.8-111.0)Male nc (nc-nc) Male 145 132.0 109.9 Female Female (92.7-129.3)20 18.1 110.5 (67.4-170.6)**Cervix Uteri Oral Cavity & Pharynx** Male 15 13.1 114.8 (64.2-189.3)2 5.1 5 6.7 75.1 Female Female (24.2-175.3)nc (nc-nc) Colon / Rectum Ovary Male 54 44.0 122.6 (92.1-160.0)Female 56 50.6 110.7 (83.6-143.8)Female 15 13.1 114.6 (64.1-189.0)**Esophagus Pancreas** 8 8.9 89.5 (38.6-176.5)11 10.9 101.1 (50.4-180.9)Male Male 6 2.8 Female Female 211.9 (77.4-461.3)13 13.3 97.8 (52.0-167.2)Hodgkin Lymphoma **Prostate** 1 2.7 123 124.7 98.7 Male nc Male (82.0-117.7) (nc-nc) 6 2.2 270.8 Female (98.9-589.4)Kidney & Renal Pelvis **Stomach** Male 17 17.5 97.2 (56.6-155.7)Male 14 8.3 168.4 (92.0-282.5)Female 12 11.1 108.4 (55.9-189.3)Female 4 5.8 (nc-nc) nc Larynx **Testis** 7 5.1 137.0 1 4.2 Male (54.9 - 282.3)Male nc (nc-nc) 1 Female 1.5 nc (nc-nc) **Leukemia Thyroid** (34.9-208.3)8 12.0 66.9 (28.8-131.8)6 6.3 Male Male 95.7 Female 8 10.1 79.4 (34.2-156.4)Female 20 20.0 99.8 (60.9-154.2)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 7 9.0 77.4 (31.0-159.4)3 Female 3.6 nc (nc-nc) Female 22 29.3 75.0 (47.0-113.6)**Lung and Bronchus** All Sites / Types 58 62.7 92.5 (70.2-119.6)445 452.9 98.3 (89.3-107.8)Male Male Female 70 68.5 102.1 (79.6-129.0)Female 487 477.6 102.0 (93.1-111.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 0bs Obs SIR 95% CI SIR 95% CI Exp Exp **Bladder, Urinary** Melanoma of Skin 1 0.7 1 0.4 Male nc (nc-nc) Male nc (nc-nc) Female 1 0.2 nc (nc-nc) Female 1 0.3 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma 0 0 0.1 Male 0.1 nc (nc-nc) Male nc (nc-nc) 0 0 0.1 Female 0.1 Female (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** 0 Male 0.0 Male 1 0.4 (nc-nc) nc (nc-nc) nc 3 Female 0 0.2 Female 2.0 nc (nc-nc) nc (nc-nc) Oral Cavity & Pharynx **Cervix Uteri** 0 0.3 Male nc (nc-nc) Female 0 0.1 0 0.1 Female (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary 0 0.9 Male nc (nc-nc) 0 0.2 Female 1 0.6 Female nc (nc-nc) nc (nc-nc) **Pancreas Esophagus** 0 1 0.2 0.2 Male Male nc (nc-nc) nc (nc-nc) 0 0.0 Female 0 0.2 Female (nc-nc) nc (nc-nc) nc Hodgkin Lymphoma **Prostate** 5 Male 0 0.0 Male 2.9 172.3 (55.5-402.2) (nc-nc) nc 0 Female 0.0 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 1 0.4 Male 0 0.2 nc (nc-nc) nc (nc-nc) Female 0 0.2 (nc-nc) Female 0 0.1 nc nc (nc-nc) Larynx **Testis** 0 0 0.1 0.0 Male Male nc (nc-nc) nc (nc-nc) Female 0 0.0 nc (nc-nc) **Leukemia Thyroid** 0 0.2 Male 0 0.1 Male nc (nc-nc) nc (nc-nc) Female 0 0.1 Female 0 0.3 (nc-nc) nc (nc-nc) nc Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 0.2 nc (nc-nc) 0 0.0 0 Female (nc-nc) Female 0.5 (nc-nc) nc nc **Lung and Bronchus** All Sites / Types Male 0 1.3 Male 12 9.7 124.3 (64.1-217.1) nc (nc-nc) Female 0 0.9 nc (nc-nc) Female 6 6.7 88.9 (32.5-193.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

	<u>Obs</u>	Exp	SIR	95% CI	, mai otandaraizoa molacilot	<u>Obs</u>	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	15.7	63.6	(30.5-117.1)	Male	19	10.5	181.2	(109.0-283.0)
Female	6	6.3	95.4	(34.8-207.7)	Female	13	8.9	146.5	(77.9-250.6)
Brain and Other Ner	vous Syst	<u>tem</u>			Multiple Myeloma				
Male	5	3.3	149.6	(48.2-349.1)	Male	4	2.6	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	0	0.4	nc	(nc-nc)	Male	17	9.1	186.6	(108.7-298.9)
Female	63	63.7	98.9	(76.0-126.5)	Female	15	8.1	186.1	(104.1-307.0)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	14	6.5	217.0	(118.5-364.0)
Female	4	2.8	nc	(nc-nc)	Female	5	3.1	161.8	(52.1-377.6)
Colon / Rectum					<u>Ovary</u>				
Male	17	20.5	83.1	(48.4-133.1)					
Female	23	21.5	106.9	(67.7-160.4)	Female	6	6.2	97.5	(35.6-212.2)
Esophagus					<u>Pancreas</u>				
Male	6	4.2	141.9	(51.8-308.8)	Male	5	5.0	100.0	(32.2-233.4)
Female	1	1.2	nc	(nc-nc)	Female	5	5.6	88.8	(28.6-207.2)
Hodgkin Lymphoma	1				<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	50	60.0	83.4	(61.9-109.9)
Female	0	1.2	nc	(nc-nc)					
Kidney & Renal Pelv	<u>ris</u>				<u>Stomach</u>				
Male	4	8.5	nc	(nc-nc)	Male	0	3.8	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	5.8	121.3	(48.6-250.0)	Male	2	3.4	nc	(nc-nc)
Female	5	4.6	107.8	(34.7-251.5)	Female	5	11.1	45.2	(14.6-105.5)
Liver and Intrahepat	ic Bile Du				Uteri Corpus and Uteru	ıs, NOS			
Male	6	4.4	137.6	(50.2-299.5)					
Female	2	1.6	nc	(nc-nc)	Female	20	14.0	142.7	(87.1-220.5)
Lung and Bronchus					All Sites / Types				
Male	36	28.9	124.4	(87.1-172.2)	Male	220	215.5	102.1	(89.0-116.5)
Female	40	30.4	131.7	(94.1-179.3)	Female	239	221.2	108.1	(94.8-122.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs Exp 95% CI Obs Exp SIR 95% CI SIR Bladder, Urinary Melanoma of Skin 14 80.2 (43.8-134.5)89.5 (44.6-160.1)Male 17.5 Male 11 12.3 9 Female 7.3 124.0 (56.6-235.4)Female 6 12.8 46.8 (17.1-102.0)**Brain and Other Nervous System Multiple Myeloma** 3 2 2.8 Male 4.4 nc (nc-nc) Male nc (nc-nc) 2 3 Female 4.1 Female 2.4 (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 1 0.5 Male 13 11.0 117.9 (62.7-201.7)nc (nc-nc) 90 72.9 Female 10 99.5 Female 123.5 (99.3-151.8)10.1 (47.6-183.0)**Cervix Uteri Oral Cavity & Pharynx** 9 Male 7.3 123.1 (56.2-233.8)3 3.5 4 3.8 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 19 22.6 84.1 (50.6-131.3) 25 7 Female 25.1 99.7 (64.5-147.2)Female 7.8 90.2 (36.1-185.8)**Esophagus** Pancreas Pancreas 7 5 4.6 108.3 (34.9-252.7)5.5 126.7 (50.7-261.0)Male Male Female 3 Female 1 1.4 (nc-nc) 6.5 nc nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 3.6 82 65.6 125.1 (99.5-155.2) nc (nc-nc) Male Female 1 3.5 nc (nc-nc) Kidney & Renal Pelvis **Stomach** Male 11 9.3 117.8 (58.7-210.9)Male 3 4.3 nc (nc-nc) Female 6.0 117.5 (47.1-242.1)Female 2 2.8 nc (nc-nc) Larynx **Testis** 5 4 2.7 6.0 83.4 Male Male (26.9-194.6)nc (nc-nc) 2 8.0 Female nc (nc-nc) **Leukemia Thyroid** 6 7.5 79.5 (29.0-173.1)3 4.4 Male Male (nc-nc) nc Female 2 5.9 Female 10 16.6 60.3 (28.9-110.9)nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS 2 Male 4.9 nc (nc-nc)

• Obs = observed case count; Exp = expected case count;

1.8

31.7

34.5

2

16

21

Female

Male

Female

Lung and Bronchus

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

(28.9 - 82.1)

(37.6-93.0)

Female

Male

Female

All Sites / Types

17

234

235

16.4

248.5

267.6

103.7

94.2

87.8

(60.4-166.1)

(82.5-107.1)

(77.0-99.8)

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc

50.6

60.8

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	, mai Gtandaraizoa molacilo	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	32	33.1	96.7	(66.1-136.6)	Male	23	22.2	103.7	(65.7-155.6)
Female	14	12.9	108.9	(59.5-182.7)	Female	25	18.1	138.1	(89.3-203.8)
Brain and Other No	ervous Sys	stem_			Multiple Myeloma				
Male	10	7.0	143.0	(68.5-263.1)	Male	5	5.5	90.8	(29.3-211.8)
Female	4	5.7	nc	(nc-nc)	Female	5	4.3	116.9	(37.7-272.8)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	3	1.0	nc	(nc-nc)	Male	20	19.2	104.1	(63.5-160.7)
Female	120	135.8	88.4	(73.3-105.7)	Female	17	16.6	102.3	(59.5-163.8)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	17	14.3	118.8	(69.1-190.2)
Female	2	5.6	nc	(nc-nc)	Female	1	6.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	37	43.7	84.7	(59.6-116.8)					
Female	38	44.3	85.8	(60.7-117.8)	Female	16	13.0	123.5	(70.6-200.6)
Esophagus					<u>Pancreas</u>				
Male	11	9.2	119.1	(59.4-213.1)	Male	13	10.7	121.6	(64.7-208.0)
Female	3	2.5	nc	(nc-nc)	Female	14	11.5	121.5	(66.4-203.9)
Hodgkin Lymphon	<u>1a</u>				<u>Prostate</u>				
Male	3	2.9	nc	(nc-nc)	Male	175	131.8	132.8	(113.8-154.0)
Female	2	2.3	nc	(nc-nc)					
Kidney & Renal Pe	<u>lvis</u>				Stomach				
Male	13	18.5	70.4	(37.4-120.3)	Male	12	8.1	148.5	(76.7-259.5)
Female	12	10.7	111.7	(57.7-195.2)	Female	3	5.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	4	5.3	nc	(nc-nc)	Male	5	4.3	115.6	(37.3-269.9)
Female	0	1.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	12	12.1	99.5	(51.3-173.8)	Male	10	7.0	143.1	(68.5-263.2)
Female	11	9.4	116.9	(58.3-209.2)	Female	32	22.5	142.5	(97.4-201.1)
Liver and Intrahep	atic Bile D	<u>ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	8	9.7	82.3	(35.5-162.3)					
Female	0	3.2	nc	(nc-nc)	Female	36	30.2	119.4	(83.6-165.3)
Lung and Bronchu	<u>IS</u>				All Sites / Types				
Male	35	61.7	56.7	(39.5-78.8)	Male	479	461.5	103.8	(94.7-113.5)
Female	48	62.6	76.6	(56.5-101.6)	Female	441	460.5	95.8	(87.0-105.1)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

 ^{95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

		Observe	d and Exp	ected Case Co	unts, with Standardized Incidence	Ratios, 200	4-2008		
	<u>Obs</u>	Exp	SIR	95% CI		<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	1	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Brain and Other Nervou	ıs System				Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	1	0.4	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	5	1.1	448.1	(144.4-1045.8)
Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis					<u>Stomach</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Liver and Intrahepatic E	Bile Ducts				Uteri Corpus and Uterus, NC	<u>)S</u>			
Male	0	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	0	0.5	nc	(nc-nc)	Male	8	4.0	201.0	(86.5-396.0)
Female	0	0.5	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs SIR 95% CI Obs Exp SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 58 116.9 (88.8-151.1)34 30.7 110.7 Male 49.6 (76.7-154.7)20 21.4 93.4 Female (57.0-144.3)Female 34 26.9 126.2 (87.4-176.4)**Brain and Other Nervous System Multiple Myeloma** 9 97.8 6 7.8 76.9 Male 9.2 (44.6-185.7)Male (28.1-167.4)5 8.4 59.8 Female 11 7.0 158.2 (78.9 - 283.2)Female (19.3-139.5)Non-Hodgkin Lymphoma **Breast** 0 1.4 Male 29 26.7 108.7 (72.8-156.1) Male nc (nc-nc) 220 197.1 Female 98.1 Female 111.6 (97.3-127.4)26 26.5 (64.0-143.7)Oral Cavity & Pharynx **Cervix Uteri** 12 18.1 66.2 Male (34.2-115.7)3 8.0 9.8 142.7 Female Female 14 (77.9-239.4)nc (nc-nc) Colon / Rectum Ovary Male 58 62.1 93.4 (71.0-120.8)82 23 Female 72.1 113.8 (90.5-141.3) Female 19.4 118.7 (75.2-178.1) **Esophagus Pancreas** 102.8 15.4 97.3 13 12.7 (54.7-175.7)15 (54.4-160.5)Male Male 5 4.2 Female Female 119.8 (38.6-279.6)20 19.1 104.6 (63.8-161.5)Hodgkin Lymphoma **Prostate** 2 4.0 139 178.6 77.8 (65.4-91.9)Male nc (nc-nc) Male 4 Female 3.3 nc (nc-nc) Kidney & Renal Pelvis **Stomach** Male 20 24.8 80.6 (49.2-124.4)Male 9 11.8 76.2 (34.8-144.6)Female 12 16.7 71.9 (37.1-125.7)Female 7 8.2 85.3 (34.2-175.8)Larynx **Testis** (30.3-180.7)9 6 7.2 83.0 6.5 Male Male 137.7 (62.8-261.5)3 2.3 Female nc (nc-nc) **Leukemia Thyroid** 18 16.8 106.9 (63.3-168.9)10 9.1 109.9 Male Male (52.6-202.1)Female 16 14.7 109.1 (62.3-177.2)Female 31 31.2 99.3 (67.5-141.0) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 9 12.6 71.6 (32.7-135.9)5 Female 5.2 97.0 (31.3-226.4)Female 36 43.9 82.0 (57.4-113.5)**Lung and Bronchus** All Sites / Types 74 90.4 81.9 (64.3-102.8)583 645.6 90.3 (83.1-97.9)Male Male Female 78 103.2 75.6 (59.7-94.3)Female 717 707.0 101.4 (94.1-109.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	4.8	146.0	(58.5-300.8)	Male	2	3.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>em</u>			Multiple Myeloma				
Male	1	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	8.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	19	19.8	96.2	(57.9-150.2)	Female	2	2.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	1	2.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	4	6.6	nc	(nc-nc)					
Female	7	5.4	129.3	(51.8-266.5)	Female	0	1.8	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	3	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	20	20.2	99.2	(60.6-153.2)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal Pelv	<u>is</u>				<u>Stomach</u>				
Male	4	3.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	8.0	nc	(nc-nc)	Male	4	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	6	3.8	157.2	(57.4-342.1)
Liver and Intrahepat	ic Bile Du	<u>cts</u>			Uteri Corpus and Uterus,	NOS			
Male	1	1.6	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	7	4.3	164.3	(65.8-338.6)
Lung and Bronchus					All Sites / Types				
Male	5	9.2	54.6	(17.6-127.5)	Male	65	71.2	91.3	(70.4-116.3)
Female	10	8.1	123.5	(59.1-227.1)	Female	71	63.6	111.7	(87.2-140.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

	Obs	Exp	Served and Ex	95% CI	, with Standardized incluence	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary	<u> </u>	<u>=x4</u>	<u> </u>	<u> </u>	Melanoma of Skin	<u> </u>	<u>=xb</u>	<u> </u>	<u> </u>
Male	4	2.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	4	0.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Brain and Other Nei				(/	Multiple Myeloma				(/
Male	3	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>				,	Non-Hodgkin Lymphoma	1			,
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	7	10.3	68.2	(27.3-140.5)	Female	6	1.2	504.9	(184.4-1099.0)
Cervix Uteri				,	Oral Cavity & Pharynx				
					Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	6	3.3	179.8	(65.6-391.3)					
Female	4	3.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	8.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	8.0	nc	(nc-nc)
Hodgkin Lymphoma	<u>a</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	10.3	87.3	(39.8-165.7)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pel	<u>vis</u>				<u>Stomach</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	8.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Liver and Intrahepa	tic Bile Du				Uteri Corpus and Uterus,	NOS			
Male	0	0.8	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	5	2.2	226.3	(72.9-528.1)
Lung and Bronchus	=				All Sites / Types				
Male	4	4.7	nc	(nc-nc)	Male	34	36.1	94.2	(65.2-131.6)
Female	2	4.5	nc	(nc-nc)	Female	37	33.8	109.3	(77.0-150.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

	<u>Obs</u>	Exp	SIR	95% CI		<u>Obs</u>	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Brain and Other Nerv	ous Syste	<u>em</u>			Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	11	7.9	139.1	(69.4-249.0)	Female	0	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	5	2.9	173.1	(55.8-403.9)					
Female	1	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	8.2	109.4	(49.9-207.8)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelv	<u>is</u>				<u>Stomach</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Liver and Intrahepati	c Bile Duc	<u>ets</u>			Uteri Corpus and Uterus,	<u>NOS</u>			
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	4	3.9	nc	(nc-nc)	Male	25	29.5	84.8	(54.9-125.2)
Female	0	3.3	nc	(nc-nc)	Female	24	25.4	94.4	(60.5-140.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

	<u>Obs</u>	Exp	SIR	95% CI	min Gtandaraizoa moidonos	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	13.5	118.3	(67.6-192.2)	Male	8	9.6	83.5	(35.9-164.5)
Female	5	4.7	106.1	(34.2-247.7)	Female	6	7.8	76.5	(27.9-166.4)
Brain and Other Ner	rvous Sys	tem_			Multiple Myeloma				
Male	3	3.1	nc	(nc-nc)	Male	5	2.3	219.7	(70.8-512.7)
Female	7	2.5	285.4	(114.4-588.2)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>ma</u>			
Male	0	0.4	nc	(nc-nc)	Male	6	8.2	73.1	(26.7-159.1)
Female	81	57.0	142.0	(112.8-176.5)	Female	10	6.4	155.9	(74.6-286.7)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	6	6.1	98.9	(36.1-215.3)
Female	2	2.6	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	11	18.1	60.8	(30.3-108.9)					
Female	18	15.9	113.5	(67.2-179.4)	Female	11	5.3	207.4	(103.4-371.2)
Esophagus					<u>Pancreas</u>				
Male	0	3.9	nc	(nc-nc)	Male	6	4.4	136.2	(49.7-296.4)
Female	0	0.9	nc	(nc-nc)	Female	5	4.1	121.2	(39.1-282.9)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	69	54.7	126.1	(98.1-159.5)
Female	2	1.1	nc	(nc-nc)					
Kidney & Renal Pelv	<u>vis</u>				<u>Stomach</u>				
Male	8	7.9	100.7	(43.4-198.5)	Male	5	3.3	149.4	(48.2-348.8)
Female	3	4.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	2.2	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	5.1	137.6	(55.1-283.6)	Male	7	3.3	214.8	(86.0-442.5)
Female	1	3.7	nc	(nc-nc)	Female	16	10.8	148.3	(84.7-240.8)
Liver and Intrahepat	tic Bile Du	<u>ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	5	4.1	122.9	(39.6-286.8)					
Female	2	1.2	nc	(nc-nc)	Female	10	12.7	78.9	(37.8-145.1)
Lung and Bronchus	<u>i</u>				All Sites / Types				
Male	16	25.6	62.4	(35.7-101.4)	Male	195	194.0	100.5	(86.9-115.7)
Female	27	24.5	110.4	(72.7-160.6)	Female	224	185.8	120.6	(105.3-137.4)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs SIR 95% CI Obs Exp SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 21 (89.3-220.6)6 8.7 68.8 Male 14.6 144.3 Male (25.1-149.7)9 Female 5.7 156.9 (71.6-297.9)Female 7 6.9 101.7 (40.7-209.6)**Brain and Other Nervous System Multiple Myeloma** 0 2.3 Male 4 2.6 nc (nc-nc) Male nc (nc-nc) 0 5 Female 2.2 Female 1.9 270.0 (nc-nc) (87.0-630.1)nc Non-Hodgkin Lymphoma **Breast** Male 0 0.4 Male 6 7.7 77.7 (28.4-169.0)nc (nc-nc) 37 50.2 Female 6 Female 73.7 (51.9-101.5)7.0 85.3 (31.1-185.6)**Cervix Uteri Oral Cavity & Pharynx** 7 Male 5.1 136.1 (54.5-280.4)1 2.0 1 2.5 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 16 18.1 88.4 (50.5-143.6)24 8 Female 19.6 122.6 (78.6-182.5)Female 5.0 160.1 (68.9-315.4) **Esophagus** Pancreas Pancreas 7 6 133.9 3.6 195.1 (78.2-402.0)4.5 (48.9-291.5)Male Male 2 Female 6 5.2 Female 1.1 (nc-nc) 115.8 (42.3-252.1) nc Hodgkin Lymphoma **Prostate** Male 3 1.1 50 50.0 100.1 (nc-nc) Male (74.3-131.9) nc Female 1 0.9 nc (nc-nc) Kidney & Renal Pelvis **Stomach** Male 6 7.0 85.7 (31.3-186.5)Male 3 3.5 nc (nc-nc) Female 4.3 (nc-nc) Female 1 2.3 nc nc (nc-nc) **Larynx Testis** 2 2.1 1 Male Male 1.6 nc (nc-nc) nc (nc-nc) 0 0.6 Female nc (nc-nc) **Leukemia Thyroid** 3 5.0 0 2.5 Male nc (nc-nc) Male (nc-nc) nc Female 7 3.9 177.4 (71.1-365.5) Female 4 7.6 nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 3 3.6 nc (nc-nc) 0 Female 1.4 nc (nc-nc) Female 10 11.1 90.5 (43.3-166.4)**Lung and Bronchus** All Sites / Types Male 31 25.8 120.0 181 184.4 98.1 (84.4-113.5)(81.5-170.3) Male

• Obs = observed case count; Exp = expected case count;

26.8

Female

34

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(87.8-177.3)

Shading indicates the statistical significance of the SIR at 95% level of probability;

126.9

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

171

183.9

93.0

(79.6-108.0)

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs 95% CI Obs SIR 95% CI Exp SIR Exp Bladder, Urinary Melanoma of Skin 51 40.5 126.1 (93.9-165.8) 28 27.0 103.8 (69.0-150.1) Male Male 13 Female 16.8 77.2 (41.1-132.1)Female 26 23.3 111.7 (72.9-163.7)**Brain and Other Nervous System Multiple Myeloma** 14 162.1 3 6.6 Male 8.6 (88.5-272.0) Male nc (nc-nc) 5 7.4 6 Female 67.7 (21.8-158.1)Female 5.5 109.4 (40.0-238.2)Non-Hodgkin Lymphoma **Breast** 1 1.1 Male 18 23.4 76.9 (45.5-121.5)Male nc (nc-nc) 180 163.6 21 Female 110.0 (94.5-127.3)Female 21.4 97.9 (60.6-149.7)**Cervix Uteri Oral Cavity & Pharynx** 24 Male 16.3 147.0 (94.2-218.8)3 7.2 4 Female Female 8.1 nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 54 52.1 103.6 (77.8-135.2)23 Female 51 57.4 88.9 (66.2-116.9)Female 16.0 143.8 (91.1-215.8) **Esophagus Pancreas** 12 12.8 93.5 11 10.8 101.8 (50.7-182.1) (48.3-163.4)Male Male 3 (nc-nc) 9 Female 3.3 Female 15.1 59.8 (27.3-113.5) nc **Hodgkin Lymphoma Prostate** 5 4.2 118.4 (38.1-276.2)Male 134 152.9 87.6 Male (73.4-103.8) 1 3.3 Female nc (nc-nc) Kidney & Renal Pelvis Stomach Male 26 21.7 119.6 (78.1-175.2)Male 12 9.8 122.5 (63.2-213.9)Female 14 13.5 103.7 (56.7-174.1) Female 4 6.5 nc (nc-nc) Larynx **Testis** 6 7 6.2 96.5 7.1 98.6 Male (35.2-210.1)Male (39.5-203.2)3 Female 1.8 nc (nc-nc) **Leukemia Thyroid** 15 14.8 101.1 6 8.7 69.0 (25.2-150.2)Male (56.5-166.8) Male Female 13 12.3 105.5 (56.1-180.5) Female 25 28.6 87.4 (56.5-129.0)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 11.0 126.9 14 (69.3-213.0) Female 7 4.1 169.0 (67.7-348.2)Female 28 36.2 77.4 (51.4-111.9) **Lung and Bronchus** All Sites / Types Male 104 74.4 139.7 (114.1-169.3)569 552.6 103.0 (94.7-111.8)Male Female 94 80.7 116.4 (94.1-142.5) Female 564 579.6 97.3 (89.4-105.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs Exp 95% CI Obs SIR 95% CI SIR Exp Bladder, Urinary Melanoma of Skin 22.1 15 67.9 (38.0-112.0) 8 13.3 60.3 (26.0-118.8)Male Male 8.3 8 Female 7 84.0 (33.7-173.1)Female 10.3 77.8 (33.5-153.3)**Brain and Other Nervous System Multiple Myeloma** 5 128.2 3 Male 3.9 (41.3-299.2)Male 3.4 nc (nc-nc) 7 2 2.7 Female 3.2 215.4 (86.3-443.8)Female (nc-nc) nc Non-Hodgkin Lymphoma **Breast** 9 Male 1 0.6 Male 11.6 77.4 (35.3-146.9)nc (nc-nc) 60 77.0 7 10.3 Female 77.9 (59.4-100.3)Female 67.8 (27.2-139.7)**Cervix Uteri Oral Cavity & Pharynx** 9 Male 8.0 112.7 (51.4-214.0)2 3.0 2 3.8 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary 33 27.4 120.3 (82.8-168.9)Male 32 9 Female 28.1 114.1 (78.0-161.0)Female 7.6 118.5 (54.1-225.0)**Esophagus** <u>Pancreas</u> 7 6 6.9 102.0 5.6 106.6 (38.9-232.1)(40.9-210.2)Male Male 2 12 Female 1.6 Female 7.4 161.1 (83.2-281.5)nc (nc-nc) **Hodgkin Lymphoma Prostate** Male 2 1.6 Male 78 79.6 98.0 (77.5-122.3)nc (nc-nc) 0 Female 1.3 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 12 10.9 110.5 (57.0-193.1)Male 6 5.2 115.0 (42.0-250.4)Female 5 6.5 76.9 (24.8-179.4)Female 3 3.2 nc (nc-nc) Larynx **Testis** 3 3.2 3 2.3 Male Male nc (nc-nc) nc (nc-nc) 0.9 Female 1 nc (nc-nc) **Leukemia Thyroid** (29.8-177.4) (43.1-312.2) 6 7.4 81.5 5 3.7 133.8 Male Male Female 5.7 Female 16 11.7 137.1 (78.3-222.7)nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 6 5.6 107.7 (39.3-234.5)0 2.0 Female (nc-nc) Female 20 17.4 115.0 (70.2-177.6)nc **Lung and Bronchus** All Sites / Types 40 40.1 99.7 278 284.3 97.8 (86.6-110.0)Male (71.2-135.8)Male

• Obs = observed case count; Exp = expected case count;

40.3

Female

55

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(102.9-177.8)

Shading indicates the statistical significance of the SIR at 95% level of probability;

136.6

nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

265

275.1

96.3

(85.1-108.7)

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs SIR 95% CI Obs SIR 95% CI Exp Exp Bladder, Urinary Melanoma of Skin 9 5.6 159.5 (72.8-302.9)3.4 Male Male 4 nc (nc-nc) 1 2.6 Female 2.1 nc (nc-nc) Female 4 nc (nc-nc) **Brain and Other Nervous System Multiple Myeloma** 0 2 0.9 Male 1.0 nc (nc-nc) Male nc (nc-nc) 0 0.7 1 8.0 Female Female (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.2 (nc-nc) Male 1 3.0 (nc-nc) nc nc 15 20.1 74.7 Female 2 2.6 Female (41.8-123.2)(nc-nc) nc **Cervix Uteri Oral Cavity & Pharynx** 3 2.1 Male nc (nc-nc) 0 0.8 1 1.0 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 8 7.0 113.9 (49.0-224.4)5 2.0 Female 6.7 74.5 (24.0-173.8)Female 1 nc (nc-nc) **Esophagus** Pancreas Pancreas 1 4 1.5 1.8 Male nc (nc-nc) Male nc (nc-nc) 0 2 Female 0.4 (nc-nc) Female 1.8 (nc-nc) nc nc Hodgkin Lymphoma **Prostate** 9 42.7 Male 1 0.4 Male 21.1 (19.5-81.1)(nc-nc) nc Female 1 0.3 nc (nc-nc) Kidney & Renal Pelvis **Stomach** Male 5 2.8 177.5 (57.2-414.3)Male 1 1.3 nc (nc-nc) Female 2 1.7 Female 1 8.0 nc (nc-nc) nc (nc-nc) Larynx **Testis** 3 0.8 0 0.6 Male Male nc (nc-nc) nc (nc-nc) 0 0.2 Female nc (nc-nc) **Leukemia Thyroid** Male 2 1.9 Male 1.0 nc (nc-nc) 1 (nc-nc) nc Female 3 1.4 Female 2 3.1 nc (nc-nc) nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 1.4 nc (nc-nc) 2 Female 0.5 nc (nc-nc) Female 7 4.6 150.7 (60.4-310.6)**Lung and Bronchus** All Sites / Types Male 9 10.4 86.4 (39.4-164.1)70 73.8 94.8 (73.9-119.8)Male Female 14 10.6 131.8 (72.0-221.2)Female 69 70.4 98.1 (76.3-124.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 0<u>bs</u> Obs Exp 95% CI SIR 95% CI SIR Exp **Bladder, Urinary** Melanoma of Skin 4 6.3 3 Male nc (nc-nc) Male 4.3 nc (nc-nc) 2 Female 2.8 nc (nc-nc) Female 5 3.7 134.2 (43.2-313.2)**Brain and Other Nervous System Multiple Myeloma** 2 2 Male 1.4 nc (nc-nc) Male 1.0 nc (nc-nc) 0.9 Female 1 1.2 Female 1 (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.2 Male 2 3.7 (nc-nc) nc (nc-nc) nc 20 26.1 Female 3 3.5 Female 76.7 (46.9-118.5)nc (nc-nc) Oral Cavity & Pharynx **Cervix Uteri** 2.6 Male 1 nc (nc-nc) 0 2 1.3 Female 1.1 Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 5 8.2 60.9 (19.6-142.1)13 Female 9.3 139.2 (74.0-238.0)Female 4 2.6 nc (nc-nc) **Esophagus** <u>Pancreas</u> 1.7 2 2.0 1 Male nc (nc-nc) Male nc (nc-nc) 0 0.5 2.5 Female (nc-nc) Female 1 (nc-nc) nc nc Hodgkin Lymphoma **Prostate** Male 0 0.7 26 24.2 107.5 (70.2-157.6) Male nc (nc-nc) Female 1 0.5 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 1 3.5 Male 2 1.5 nc (nc-nc) nc (nc-nc) Female 5 2.2 230.5 (74.3-538.0)Female 0 1.1 nc (nc-nc) Larynx **Testis** 1.0 0 1.2 Male 1 Male nc (nc-nc) nc (nc-nc) 0 0.3 Female nc (nc-nc) **Leukemia Thyroid** 2.4 Male 1.4 Male (nc-nc) 1 (nc-nc) nc nc Female 2.0 Female 5 4.6 109.6 (35.3-255.9)nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 1.8 nc (nc-nc) 0 0.7 9 Female nc (nc-nc) Female 5.7 157.7 (72.0-299.4)**Lung and Bronchus** All Sites / Types 21 11.8 178.3 (110.3-272.6)84 87.7 95.8 (76.4-118.6)Male Male Female 12 13.1 91.6 (47.3-160.0) Female 96 93.3 102.9 (83.4-125.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

	Obs		SIR	95% CI	, with Standardized incluence			SIR	95% CI
Bladder, Urinary	ODS	<u>Exp</u>	SIK	93 /6 CI	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	SIK	93 /6 CI
	0.5	74.0	444.0	(04.4.444.0)		Ε0	40.0	440.0	(00.0.450.0)
Male	85	74.6	114.0	(91.1-141.0)	Male	50	42.2	118.6	(88.0-156.3)
Female	22	25.9	84.9	(53.2-128.5)	Female	45	30.7	146.8	(107.0-196.4)
Brain and Other No	-		100.1	(== = 0.1.1.0)	Multiple Myeloma	_	44.0	20.4	(0.1.0.100.0)
Male	16	12.1	132.1	(75.5-214.6)	Male	7	11.3	62.1	(24.9-128.0)
Female	13	9.8	133.2	(70.8-227.8)	Female	15	8.4	178.7	(100.0-294.8)
<u>Breast</u>					Non-Hodgkin Lymphor				
Male	0	2.0	nc	(nc-nc)	Male	41	37.5	109.4	(78.5-148.5)
Female	247	230.1	107.3	(94.4-121.6)	Female	25	31.6	79.0	(51.1-116.6)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	29	24.2	120.0	(80.4-172.4)
Female	9	8.6	104.7	(47.8-198.7)	Female	19	11.6	163.7	(98.5-255.7)
Colon / Rectum					<u>Ovary</u>				
Male	75	89.9	83.5	(65.6-104.6)					
Female	92	85.6	107.5	(86.6-131.8)	Female	22	22.8	96.5	(60.5-146.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	17.9	100.5	(59.5-158.9)	Male	17	22.6	75.2	(43.8-120.4)
Female	1	5.1	nc	(nc-nc)	Female	37	23.1	160.2	(112.8-220.8)
Hodgkin Lymphon	<u>1a</u>				<u>Prostate</u>				
Male	4	4.8	nc	(nc-nc)	Male	361	249.2	144.9	(130.3-160.6)
Female	4	3.8	nc	(nc-nc)					
Kidney & Renal Pe	lvis			, ,	Stomach				
Male	 31	34.0	91.3	(62.0-129.6)	Male	13	17.3	74.9	(39.9-128.1)
Female	16	19.9	80.3	(45.9-130.4)	Female	7	9.7	71.9	(28.8-148.2)
<u>Larynx</u>				,	Testis				,
Male	7	10.2	68.9	(27.6-142.0)	Male	7	6.8	103.5	(41.5-213.2)
Female	2	2.7	nc	(nc-nc)					(*****=***=/
<u>Leukemia</u>				(/	<u>Thyroid</u>				
Male	30	24.1	124.7	(84.1-178.0)	Male	3	11.1	nc	(nc-nc)
Female	23	17.3	133.1	(84.3-199.7)	Female	18	34.0	53.0	(31.4-83.8)
Liver and Intrahep			100.1	(01.0100.1)	Uteri Corpus and Uteru		01.0	00.0	(01.1 00.0)
Male	13	17.2	75.5	(40.1-129.1)	oteri corpus una oteri	10, 110 <u>0</u>			
Female	7	6.1	113.9	(45.6-234.8)	Female	45	51.9	86.6	(63.2-115.9)
Lung and Bronchu		0.1	110.5	(40.0 204.0)	All Sites / Types	-1 0	51.5	00.0	(00.2-110.3)
Male	115	132.8	86.6	(71.5-103.9)	Male	1009	914.5	110.3	(103.6-117.4)
Female	129	126.3	102.2	(85.3-121.4)	Female	868	834.4	104.0	(97.2-111.2)
remale	129	120.3	102.2	(00.0-121.4)	remale	000	034.4	104.0	(31.2-111.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 0<u>bs</u> Obs Exp 95% CI SIR 95% CI SIR Exp **Bladder, Urinary** Melanoma of Skin 6 5.5 109.1 (39.8-237.5)2 3.6 Male Male nc (nc-nc) Female 1 2.0 nc (nc-nc) Female 1 2.8 nc (nc-nc) **Brain and Other Nervous System Multiple Myeloma** 1.1 0.9 Male 4 nc (nc-nc) Male 1 nc (nc-nc) 0 0 Female 0.9 Female 0.6 (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 1 0.2 Male 2 3.1 (nc-nc) nc (nc-nc) nc 17 19.7 Female 3 2.5 Female 86.2 (50.2-138.0)nc (nc-nc) Oral Cavity & Pharynx **Cervix Uteri** 2 2.2 Male nc (nc-nc) 0 0.9 0 0.9 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary (22.7-164.6) Male 5 7.1 70.5 0 Female 6 6.6 90.3 (33.0-196.6)Female 1.9 nc (nc-nc) **Pancreas Esophagus** 3 0 1.4 1.7 Male nc (nc-nc) Male nc (nc-nc) 0 0.4 3 Female (nc-nc) Female 1.7 (nc-nc) nc nc Hodgkin Lymphoma **Prostate** Male 0 0.5 Male 16 20.0 80.1 (45.7-130.1) nc (nc-nc) Female 1 0.4 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 4 2.9 Male 1 1.3 nc (nc-nc) nc (nc-nc) Female 0 1.6 (nc-nc) Female 0 0.7 nc nc (nc-nc) Larynx **Testis** 2 8.0 0.8 Male 1 Male nc (nc-nc) nc (nc-nc) 0.2 Female nc (nc-nc) **Leukemia Thyroid** (110.6-659.4)6 2.0 302.9 Male 1.1 Male 1 (nc-nc) nc Female 2 1.4 Female 1 3.4 nc (nc-nc) nc (nc-nc) Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 1.5 nc (nc-nc) 0 6 Female 0.5 nc (nc-nc) Female 4.3 140.7 (51.4-306.3)**Lung and Bronchus** All Sites / Types

• Obs = observed case count; Exp = expected case count;

10.0

9.5

9

7

Male

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(41.0-170.5)

(29.4-151.3)

Shading indicates the statistical significance of the SIR at 95% level of probability;

89.8

73.5

• nc = The SIR and 95% CI were not calculated when Obs < 5;

72

53

Male

Female

73.5

68.6

97.9

77.3

(76.6-123.3)

(57.9-101.1)

Becket

	<u>Obs</u>	Exp	SIR	95% CI		<u>Obs</u>	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	2.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>tem</u>			Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	7	7.1	98.4	(39.4-202.8)	Female	2	8.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	2	3.0	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	9.5	52.9	(17.0-123.4)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelv					<u>Stomach</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>	_			, ,	<u>Thyroid</u>	_			, ,
Male	0	8.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Liver and Intrahepat				, ,	Uteri Corpus and Uterus,	<u>NOS</u>			
Male	0	0.7	nc	(nc-nc)		_	4 =	0000	(07.0.707.0)
Female	0	0.2	nc	(nc-nc)	Female	5	1.7	302.9	(97.6-707.0)
Lung and Bronchus	40	4.4	005.0	(400 4 445 0)	All Sites / Types	00	00.0	00 7	(57.0.405.0)
Male	10	4.4	225.8	(108.1-415.2)	Male	28	32.3	86.7	(57.6-125.3)
Female	4	3.3	nc	(nc-nc)	Female	27	23.6	114.4	(75.3-166.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

	<u>Obs</u>	Exp	SIR	95% CI	, mai Gtandaraizoa molacilo	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	20.8	76.8	(43.9-124.7)	Male	20	12.0	167.2	(102.1-258.3)
Female	3	6.0	nc	(nc-nc)	Female	12	7.4	161.5	(83.3-282.0)
Brain and Other Ner	vous Sys	<u>tem</u>			Multiple Myeloma				
Male	2	3.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	2	0.6	nc	(nc-nc)	Male	9	10.5	85.3	(38.9-162.0)
Female	65	56.4	115.3	(89.0-147.0)	Female	5	7.4	67.6	(21.8-157.7)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	8	7.0	114.4	(49.2-225.4)
Female	2	2.2	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	25	25.4	98.5	(63.7-145.4)					
Female	19	20.2	94.1	(56.6-146.9)	Female	6	5.5	108.8	(39.7-236.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.1	nc	(nc-nc)	Male	7	6.4	109.9	(44.0-226.4)
Female	2	1.1	nc	(nc-nc)	Female	5	5.4	93.4	(30.1-218.1)
Hodgkin Lymphoma	1				<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	62	71.3	87.0	(66.7-111.5)
Female	2	0.9	nc	(nc-nc)					
Kidney & Renal Pelv	<u>ris</u>				<u>Stomach</u>				
Male	11	9.7	112.9	(56.3-202.1)	Male	6	4.9	123.0	(44.9-267.7)
Female	4	4.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	2.9	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	10	6.8	148.0	(70.8-272.1)	Male	5	3.2	157.7	(50.8-368.1)
Female	3	4.1	nc	(nc-nc)	Female	7	8.5	82.0	(32.8-168.9)
Liver and Intrahepat	ic Bile Du				Uteri Corpus and Uteru	ıs, NOS			
Male	5	4.9	101.4	(32.7-236.7)					
Female	3	1.4	nc	(nc-nc)	Female	16	12.7	125.6	(71.7-204.0)
Lung and Bronchus					All Sites / Types				
Male	31	37.3	83.1	(56.5-118.0)	Male	246	258.7	95.1	(83.6-107.8)
Female	28	28.6	97.7	(64.9-141.3)	Female	198	199.1	99.5	(86.1-114.3)

[•] Obs = observed case count; Exp = expected case count;

[•] SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

[•] Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs Exp SIR 95% CI Obs Exp SIR 95% CI Bladder, Urinary Melanoma of Skin 10 87.1 (41.7-160.2)6 8.1 74.0 (27.0-161.2)Male 11.5 Male 5 Female 4.0 125.2 (40.3-292.1)Female 10 6.8 146.9 (70.3-270.1)**Brain and Other Nervous System Multiple Myeloma** 2 2 Male 2.7 nc (nc-nc) Male 1.9 nc (nc-nc) 2 2.1 0 Female Female 1.4 (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.3 (nc-nc) Male 6 7.0 85.3 (31.2-185.8)nc 52 47.7 108.9 Female 3 Female (81.4-142.9)5.5 nc (nc-nc) **Cervix Uteri Oral Cavity & Pharynx** 6 Male 5.1 117.4 (42.9-255.4)1 2.3 1 2.2 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 19 15.4 123.4 (74.3-192.7)80.2 7 Female 11 13.7 (40.0-143.6)Female 4.5 156.6 (62.7-322.6)**Esophagus Pancreas** 5 3.2 1 3.7 156.0 (50.3-364.2)Male Male nc (nc-nc) Female 5 3.5 Female 1 8.0 (nc-nc) 141.6 (45.6-330.4)nc Hodgkin Lymphoma **Prostate** 2 Male 1.3 54 44.5 121.2 nc (nc-nc) Male (91.1-158.2) 0 1.0 Female nc (nc-nc) Kidney & Renal Pelvis Stomach Male 5 6.6 75.7 (24.4-176.6)Male 3 2.8 nc (nc-nc) Female 4 3.7 (nc-nc) Female 1 1.5 nc nc (nc-nc) **Larynx Testis** 0 2.2 1.8 1 Male (nc-nc) Male nc nc (nc-nc) 0 0.5 Female (nc-nc) nc **Leukemia Thyroid** Male 3 4.4 2.8 nc (nc-nc) Male 1 (nc-nc) nc

• Obs = observed case count; Exp = expected case count;

Female

Male

Male

Female

Female

Lung and Bronchus

Liver and Intrahepatic Bile Ducts

1

2

0

17

25

3.2

3.4

1.0

21.3

20.3

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

(nc-nc)

(nc-nc)

(46.5-127.9)

(79.8-182.1)

Female

Uteri Corpus and Uterus, NOS

Female

Male

Female

All Sites / Types

5

10

151

153

9.3

10.5

162.6

157.1

53.7

95.6

92.9

97.4

(17.3-125.3)

(45.8-175.8)

(78.7-108.9)

(82.6-114.1)

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc

nc

nc

79.9

123.3

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

	<u>Obs</u>	Exp	SIR	95% CI	min otaliaarai20a molaonoo	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	15	13.5	111.5	(62.4-183.9)	Male	2	9.6	nc	(nc-nc)
Female	12	4.8	250.4	(129.3-437.5)	Female	10	7.7	129.5	(62.0-238.2)
Brain and Other Ner	rvous Sys	tem_			Multiple Myeloma				
Male	5	3.1	159.3	(51.3-371.7)	Male	2	2.3	nc	(nc-nc)
Female	5	2.5	203.5	(65.6-474.9)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>ma</u>			
Male	0	0.4	nc	(nc-nc)	Male	8	8.2	97.5	(42.0-192.2)
Female	68	56.2	120.9	(93.9-153.3)	Female	9	6.5	139.0	(63.4-263.9)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	7	6.2	113.5	(45.5-233.9)
Female	5	2.5	197.0	(63.5-459.7)	Female	3	2.6	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	22	18.0	121.9	(76.4-184.5)					
Female	14	15.9	87.9	(48.0-147.5)	Female	3	5.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	2	3.9	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
Hodgkin Lymphoma	<u>a</u>				<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	78	56.6	137.7	(108.9-171.9)
Female	0	1.1	nc	(nc-nc)					
Kidney & Renal Pelv	<u>vis</u>				<u>Stomach</u>				
Male	8	8.0	100.4	(43.2-197.8)	Male	1	3.3	nc	(nc-nc)
Female	7	4.4	158.6	(63.5-326.8)	Female	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	4	2.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	5.1	136.8	(54.8-281.9)	Male	4	3.3	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	Female	5	10.4	47.9	(15.4-111.7)
Liver and Intrahepat	<u>tic Bile Dι</u>	<u>ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	4	4.1	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)	Female	16	12.8	125.2	(71.5-203.3)
Lung and Bronchus	<u>i</u>				All Sites / Types				
Male	41	25.7	159.3	(114.3-216.2)	Male	229	196.1	116.8	(102.1-132.9)
Female	42	25.0	168.2	(121.2-227.4)	Female	227	185.4	122.4	(107.0-139.4)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	min otandaraizoa molacilo	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	19	30.6	62.2	(37.4-97.1)	Male	27	18.4	146.6	(96.6-213.3)
Female	6	11.8	51.0	(18.6-111.1)	Female	20	14.8	134.7	(82.3-208.1)
Brain and Other Ne	rvous Sys	stem_			Multiple Myeloma				
Male	5	5.4	91.9	(29.6-214.4)	Male	1	4.8	nc	(nc-nc)
Female	5	4.6	107.6	(34.7-251.0)	Female	1	3.8	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	1	0.8	nc	(nc-nc)	Male	17	16.1	105.3	(61.3-168.7)
Female	121	110.4	109.6	(90.9-130.9)	Female	9	14.6	61.5	(28.1-116.7)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	5	11.0	45.6	(14.7-106.3)
Female	1	4.4	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	31	38.1	81.5	(55.3-115.6)					
Female	42	40.0	105.1	(75.7-142.0)	Female	17	10.8	157.8	(91.9-252.6)
Esophagus					<u>Pancreas</u>				
Male	2	7.7	nc	(nc-nc)	Male	7	9.5	74.0	(29.7-152.5)
Female	0	2.3	nc	(nc-nc)	Female	19	10.5	180.3	(108.5-281.6)
Hodgkin Lymphom	<u>ıa</u>				<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	113	108.1	104.5	(86.1-125.6)
Female	1	1.8	nc	(nc-nc)					
Kidney & Renal Pe	<u>lvis</u>				<u>Stomach</u>				
Male	15	14.9	100.6	(56.2-165.9)	Male	4	7.2	nc	(nc-nc)
Female	5	9.2	54.4	(17.5-127.0)	Female	4	4.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	4.4	nc	(nc-nc)	Male	5	3.3	153.0	(49.3-357.1)
Female	1	1.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	8	10.3	77.7	(33.5-153.1)	Male	9	5.2	173.1	(79.0-328.5)
Female	6	8.1	73.9	(27.0-161.0)	Female	26	17.2	151.2	(98.7-221.5)
Liver and Intrahepa	atic Bile D	<u>ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	3	7.6	nc	(nc-nc)					
Female	2	2.9	nc	(nc-nc)	Female	19	24.5	77.6	(46.7-121.1)
Lung and Bronchu	<u>s</u>				All Sites / Types				_
Male	31	55.0	56.3	(38.3-80.0)	Male	329	391.3	84.1	(75.2-93.7)
Female	36	56.2	64.1	(44.9-88.7)	Female	376	391.7	96.0	(86.5-106.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	The standard and the standard	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	4.0	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>tem</u>			Multiple Myeloma				
Male	2	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	21	18.1	116.1	(71.8-177.4)	Female	1	1.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	3	2.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	3	8.0	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	4	5.7	nc	(nc-nc)					
Female	5	4.7	106.7	(34.4-249.1)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	17.6	85.4	(47.8-140.9)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal Pelv	<u>/is</u>				Stomach				
Male	7	2.7	263.7	(105.6-543.3)	Male	0	1.0	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	8	4.0	200.1	(86.2-394.4)
Liver and Intrahepat	tic Bile Du				Uteri Corpus and Uterus,	<u>NOS</u>			
Male	1	1.4	nc	(nc-nc)					
Female	1	0.4	nc	(nc-nc)	Female	6	3.9	155.1	(56.6-337.7)
Lung and Bronchus					All Sites / Types				
Male	5	7.7	64.6	(20.8-150.8)	Male	55	62.5	88.0	(66.3-114.5)
Female	4	6.9	nc	(nc-nc)	Female	67	57.9	115.7	(89.7-146.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 <u>Obs</u> 95% CI Exp <u>SIR</u> 95% CI <u>Obs</u> Exp SIR

Bladder, Urinary					Melanoma of Skin				
Male	3	2.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>em</u>			Multiple Myeloma				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	7	10.7	65.7	(26.3-135.3)	Female	1	1.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	5	3.7	134.5	(43.4-314.0)					
Female	3	3.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Hodgkin Lymphoma	<u>l</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	12	11.7	102.9	(53.1-179.8)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelv	<u>ris</u>				Stomach_				
Male	4	1.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Liver and Intrahepat	ic Bile Du	<u>cts</u>			Uteri Corpus and Uterus,	NOS			
Male	1	0.9	nc	(nc-nc)	·				
Female	0	0.2	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Lung and Bronchus				. ,	All Sites / Types				, ,
Male	5	5.2	95.6	(30.8-223.2)	Male	43	39.8	108.0	(78.1-145.5)
	40	4.0	005.0	(00.0.070.0)		00	05.4	00.5	(04.0.407.7)

Obs = observed case count; Exp = expected case count;

4.9

Female

10

(98.6-378.8)

205.9

Female

32

35.4

90.5

(61.9-127.7)

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

	01		-		illi Standardized incidence Rati			OID.	050/ 01
	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	6	3.0	201.5	(73.6-438.5)	Male	1	1.8	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Brain and Other Nerv	vous Syst	<u>em</u>			Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	7	10.3	68.2	(27.3-140.4)	Female	1	1.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	1	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	4	3.8	nc	(nc-nc)					
Female	5	3.5	143.8	(46.3-335.6)	Female	0	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	11.4	96.8	(48.2-173.2)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelv	<u>is</u>				<u>Stomach</u>				
Male	3	1.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					, ,
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Liver and Intrahepati	ic Bile Du	cts		, ,	Uteri Corpus and Uterus,	NOS			, ,
Male	0	0.8	nc	(nc-nc)	•				
Female	0	0.3	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
Lung and Bronchus				, ,	All Sites / Types				, ,
Male	3	5.5	nc	(nc-nc)	Male	37	39.6	93.4	(65.7-128.7)
Female	2	5.0	nc	(nc-nc)	Female	30	35.4	84.7	(57.1-120.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs SIR 95% CI Obs Exp SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 50 45.4 110.2 (81.8-145.3)27 28.2 95.7 (63.1-139.3)Male 23 19.0 121.0 Female (76.7-181.6)Female 30 23.8 126.1 (85.1-180.0)**Brain and Other Nervous System Multiple Myeloma** 9 104.8 3 7.2 Male 8.6 (47.8-199.0)Male nc (nc-nc) 11 4 Female 7.5 146.3 (72.9-261.8)Female 6.2 (nc-nc) nc Non-Hodgkin Lymphoma **Breast** 2 1.3 (nc-nc) Male 32 24.7 129.6 (88.6-183.0)Male nc 154 171.9 89.6 Female 23.5 119.1 Female (76.0-104.9)28 (79.1-172.1)**Cervix Uteri Oral Cavity & Pharynx** 23 17.0 Male 135.7 (86.0-203.6)5 6.9 72.8 10 8.6 115.7 Female (23.5-169.8)Female (55.4-212.8)Colon / Rectum Ovary 62.9 Male 36 57.3 (44.0-87.1)60 92.1 17.0 Female 65.1 (70.3-118.6)Female 17 99.8 (58.1-159.9) **Esophagus Pancreas** 6 42.4 14.1 (15.5-92.3)16 11.6 137.6 (78.6-223.5)Male Male 2 Female 8 17.1 46.7 Female 3.7 nc (nc-nc) (20.1-92.0)Hodgkin Lymphoma **Prostate** 3 3.8 177 163.4 108.3 (93.0-125.5)Male nc (nc-nc) Male 3 3.2 Female nc (nc-nc) Kidney & Renal Pelvis Stomach Male 29 22.9 126.9 (85.0-182.2)Male 8 10.8 73.8 (31.8-145.5)Female 15 14.5 103.8 (58.1-171.2)Female 4 7.5 nc (nc-nc) Larynx **Testis** 4 6.6 10 5.9 169.7 Male Male (81.2 - 312.0)nc (nc-nc) 2 2.0 Female nc (nc-nc) **Leukemia Thyroid** (33.5-172.2)20 15.8 126.9 (77.5-196.0)7 8.4 83.6 Male Male Female 8 13.3 60.4 (26.0-118.9)Female 34 27.1 125.5 (86.9-175.4)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 9 11.8 76.6 (34.9-145.4)4.6 Female 7 152.4 (61.1-314.1)Female 36 37.8 95.3 (66.7-131.9)**Lung and Bronchus** All Sites / Types Male 88 82.3 107.0 (85.8-131.8) 610 593.0 102.9 (94.9-111.4)Male Female 105 89.1 117.8 (96.3-142.6)Female 620 622.2 99.7 (92.0-107.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	0	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	43	31.6	136.2	(98.5-183.4)	Male	27	23.7	113.7	(74.9-165.4)
Female	21	11.5	182.2	(112.7-278.5)	Female	18	18.9	95.2	(56.4-150.5)
Brain and Other N	ervous Sy	<u>stem</u>			Multiple Myeloma				
Male	11	7.9	139.2	(69.4-249.0)	Male	4	5.5	nc	(nc-nc)
Female	10	6.0	167.5	(80.2-308.1)	Female	5	3.9	128.1	(41.3-299.0)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	0	0.9	nc	(nc-nc)	Male	18	20.2	89.2	(52.8-141.0)
Female	128	137.1	93.4	(77.9-111.0)	Female	20	15.7	127.5	(77.8-196.8)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	21	15.6	134.7	(83.3-205.9)
Female	5	6.2	80.2	(25.9-187.3)	Female	3	6.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	48	43.4	110.6	(81.5-146.6)					
Female	36	38.8	92.8	(65.0-128.5)	Female	15	13.0	115.8	(64.8-191.0)
Esophagus Page 1					<u>Pancreas</u>				
Male	11	9.6	114.9	(57.3-205.5)	Male	11	10.6	104.2	(51.9-186.4)
Female	2	2.2	nc	(nc-nc)	Female	13	10.1	128.6	(68.4-219.9)
Hodgkin Lymphon	<u>na</u>				<u>Prostate</u>				
Male	5	3.9	127.9	(41.2-298.4)	Male	135	138.9	97.2	(81.5-115.0)
Female	2	2.8	nc	(nc-nc)					
Kidney & Renal Pe	<u>elvis</u>				Stomach .				
Male	27	19.7	137.4	(90.5-199.9)	Male	10	7.9	126.7	(60.6-232.9)
Female	10	10.6	94.1	(45.1-173.2)	Female	1	4.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	6	5.6	107.7	(39.3-234.4)	Male	11	6.7	164.5	(82.0-294.4)
Female	3	1.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	21	12.5	168.3	(104.2-257.3)	Male	8	8.4	95.4	(41.1-187.9)
Female	15	9.0	167.1	(93.5-275.7)	Female	27	25.6	105.4	(69.5-153.4)
Liver and Intrahep	atic Bile D				Uteri Corpus and Uteru	ıs, NOS			
Male	8	10.3	77.7	(33.4-153.1)					
Female	2	3.0	nc	(nc-nc)	Female	37	31.5	117.5	(82.7-162.0)
Lung and Bronchu					All Sites / Types				
Male	100	60.9	164.2	(133.6-199.8)	Male	575	477.8	120.3	(110.7-130.6)
Female	73	59.2	123.4	(96.7-155.1)	Female	491	450.3	109.0	(99.6-119.1)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

[•] Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	otaliaa aleoa molaono	<u>Obs</u>	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	7.6	158.6	(81.9-277.1)	Male	5	5.3	94.8	(30.6-221.2)
Female	4	2.8	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
Brain and Other Ner	vous Sys	<u>tem</u>			Multiple Myeloma				
Male	2	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>ma</u>			
Male	0	0.2	nc	(nc-nc)	Male	5	4.6	109.4	(35.3-255.3)
Female	26	30.8	84.4	(55.1-123.7)	Female	9	3.7	242.0	(110.4-459.3)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	1	3.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	10	10.0	99.9	(47.8-183.7)					
Female	7	9.4	74.5	(29.8-153.5)	Female	2	2.9	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	43	29.3	146.9	(106.3-197.9)
Female	0	0.7	nc	(nc-nc)					
Kidney & Renal Pelv	<u>/is</u>				Stomach				
Male	4	4.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	8	2.5	326.3	(140.5-642.9)	Female	2	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	1.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	7	5.8	121.1	(48.5-249.6)
Liver and Intrahepat	tic Bile Du				Uteri Corpus and Uteri	ıs, NOS			
Male	3	2.2	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	11	6.8	161.2	(80.4-288.5)
Lung and Bronchus	_				All Sites / Types				
Male	26	14.0	185.9	(121.4-272.3)	Male	132	106.3	124.2	(103.9-147.3)
Female	20	14.1	141.6	(86.5-218.7)	Female	119	104.2	114.2	(94.6-136.6)

Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

	<u>Obs</u>	Exp	SIR	95% CI	The standard and a more of the	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nerv	ous Syst	<u>tem</u>			Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	8	4.8	167.5	(72.1-330.1)	Female	1	0.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.6	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	1	1.7	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	5.4	148.8	(64.1-293.2)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvi	<u>is</u>				Stomach				
Male	0	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Liver and Intrahepati	c Bile Du				Uteri Corpus and Uterus,	<u>NOS</u>			
Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	2	2.4	nc	(nc-nc)	Male	18	18.4	98.0	(58.1-155.0)
Female	2	1.9	nc	(nc-nc)	Female	24	15.2	157.7	(101.0-234.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs Exp SIR 95% CI Obs Exp SIR 95% CI Bladder, Urinary Melanoma of Skin 4 3.1 5 2.6 194.6 (62.7-454.1)Male nc (nc-nc) Male Female 0 1 1.0 nc (nc-nc) Female 2.0 nc (nc-nc) **Brain and Other Nervous System Multiple Myeloma** 3 0.6 Male 0.9 nc (nc-nc) Male 1 nc (nc-nc) 0 0 0.4 Female 0.6 Female (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.1 (nc-nc) Male 1 2.2 (nc-nc) nc nc 15 14.9 100.9 Female Female (56.4-166.5)1 1.5 (nc-nc) nc **Cervix Uteri** Oral Cavity & Pharynx 4 1.8 Male nc (nc-nc) 1 0.7 1 0.6 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary Male 4 4.6 nc (nc-nc) 2 2 Female 3.6 (nc-nc) Female 1.3 nc nc (nc-nc) **Esophagus Pancreas** 0 0 1.0 1.1 Male nc (nc-nc) Male nc (nc-nc) 0 0.2 Female 3 0.9 Female (nc-nc) (nc-nc) nc nc **Prostate** Hodgkin Lymphoma Male 1 0.4 Male 12 14.9 80.6 (41.6-140.8) (nc-nc) nc Female 1 0.3 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 1 2.2 Male 0 8.0 nc (nc-nc) nc (nc-nc) Female 1 1.1 (nc-nc) Female 2 0.4 nc nc (nc-nc) Larynx **Testis** 2 1 0.6 0.6 (nc-nc) Male Male nc nc (nc-nc) 0 0.1 Female nc (nc-nc) **Leukemia Thyroid** Male 2 1.3 Male 1.0 nc (nc-nc) 1 (nc-nc) nc Female 1 0.9 (nc-nc) Female 3 3.0 nc nc (nc-nc) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 1.2 nc (nc-nc) 0 0.3 7 Female nc (nc-nc) Female 3.3 214.6 (86.0-442.2)**Lung and Bronchus** All Sites / Types

• Obs = observed case count; Exp = expected case count;

6.2

5.4

Male

Female

5

6

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(26.1-189.1)

(40.9-243.9)

Shading indicates the statistical significance of the SIR at 95% level of probability;

81.0

112.0

• nc = The SIR and 95% CI were not calculated when Obs < 5;

50

49

Male

Female

50.6

45.5

98.8

107.6

(73.3-130.2)

(79.6-142.3)

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs Exp SIR 95% CI 0<u>bs</u> SIR 95% CI Exp Bladder, Urinary Melanoma of Skin 79.3 (71.2-88.0)83.2 353 445.1 250 300.4 (73.2-94.2)Male Male 186.3 76.8 (64.7-90.4)279.9 Female 143 Female 273 97.5 (86.3-109.8)**Brain and Other Nervous System Multiple Myeloma** 74.7 (58.7-93.8)136.8 Male 74 99.0 Male 98 71.7 (111.0-166.7)86 Female 88.2 97.5 (78.0-120.4)Female 84 60.4 139.0 (110.8-172.1)Non-Hodgkin Lymphoma **Breast** 7 12.5 56.1 (22.5-115.6)Male 292 261.5 111.7 (99.2-125.2) Male 1835.5 96.4 242.0 Female 1769 (91.9-101.0)Female 212 87.6 (76.2-100.2)**Cervix Uteri** Oral Cavity & Pharynx 204 116.1 Male 175.7 (100.7-133.2)112 87.0 128.7 (106.0-154.9)99 92.0 107.6 Female Female (87.4-131.0) Colon / Rectum Ovary Male 652 571.7 114.1 (105.5-123.2)628.8 172 Female 674 107.2 (99.2-115.6)Female 181.9 94.6 (81.0-109.8) **Esophagus Pancreas** 94.5 116.3 (77.7-114.0)145 139.9 103.7 (87.5-122.0) Male 110 Male 36.1 116.1 Female 45 124.5 (90.8-166.6)Female 192 165.4 (100.2-133.7)**Hodgkin Lymphoma Prostate** Male 49 56.8 86.3 (63.8-114.1)1903 1633.6 116.5 (111.3-121.8)Male 133.2 Female 63 47.3 (102.4-170.4)Kidney & Renal Pelvis **Stomach** Male 265 236.0 112.3 (99.2-126.6)Male 127 108.0 117.6 (98.1-140.0)Female 187 152.7 122.5 (105.5-141.3)Female 105 71.4 147.1 (120.3-178.0) Larynx **Testis** 83 66.7 124.4 87 100.1 86.9 Male (99.1-154.3) Male (69.6-107.2)Female 29 20.8 139.3 (93.3-200.1)**Leukemia Thyroid** 148 168.8 87.7 (74.1-103.0)110 100.2 109.7 (90.2-132.3)Male Male Female 139 140.8 98.7 (83.0-116.5)Female 456 357.3 127.6 (116.2-139.9)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS 189.2 Male 225 118.9 (165.3-215.6)46.1 145.5 Female 67 (112.7-184.7)Female 414 406.8 101.8 (92.2-112.1) **Lung and Bronchus** All Sites / Types Male 936 810.4 115.5 (108.2-123.1)6647 6070.6 109.5 (106.9-112.2)Male

• Obs = observed case count; Exp = expected case count;

906.3

Female

874

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(90.2-103.1)

Shading indicates the statistical significance of the SIR at 95% level of probability;

96.4

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

6770

6562.4

103.2

(100.7-105.7)

Bourne

	Obs	Exp	SIR	95% CI	with Standardized incidence	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary	<u> </u>	<u></u>	<u> </u>	<u> </u>	Melanoma of Skin	<u></u>	<u> </u>	<u> </u>	<u> </u>
Male	25	25.6	97.7	(63.2-144.2)	Male	29	15.0	193.2	(129.4-277.5)
Female	19	9.3	205.0	(123.3-320.1)	Female	15	11.3	132.6	(74.2-218.8)
Brain and Other Ner				,	Multiple Myeloma				(
Male	5	4.5	111.6	(36.0-260.5)	Male	4	3.9	nc	(nc-nc)
Female	7	3.6	193.2	(77.4-398.2)	Female	6	3.0	200.1	(73.1-435.6)
<u>Breast</u>				,	Non-Hodgkin Lymphor				,
Male	0	0.7	nc	(nc-nc)	Male	 14	13.3	105.5	(57.6-177.0)
Female	91	82.9	109.8	(88.4-134.8)	Female	13	11.4	114.1	(60.7-195.1)
Cervix Uteri				,	Oral Cavity & Pharynx				,
					Male	12	8.7	138.0	(71.2-241.1)
Female	2	3.2	nc	(nc-nc)	Female	6	4.2	142.6	(52.1-310.3)
Colon / Rectum					<u>Ovary</u>				
Male	30	31.2	96.3	(64.9-137.4)					
Female	20	30.8	64.9	(39.6-100.2)	Female	13	8.3	157.1	(83.6-268.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.3	79.0	(25.5-184.4)	Male	6	7.8	76.6	(28.0-166.7)
Female	5	1.8	276.5	(89.1-645.3)	Female	7	8.3	84.7	(33.9-174.6)
Hodgkin Lymphoma	<u>l</u>				<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	108	88.8	121.6	(99.7-146.8)
Female	1	1.5	nc	(nc-nc)					
Kidney & Renal Pelv	<u>ris</u>				Stomach				
Male	11	12.1	91.0	(45.4-162.8)	Male	7	6.0	116.8	(46.8-240.7)
Female	6	7.2	83.8	(30.6-182.4)	Female	5	3.5	142.5	(45.9-332.6)
<u>Larynx</u>					<u>Testis</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	15	8.6	175.4	(98.1-289.3)	Male	1	4.2	nc	(nc-nc)
Female	10	6.3	158.1	(75.7-290.7)	Female	12	12.7	94.3	(48.7-164.8)
Liver and Intrahepat	ic Bile Du	<u>ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	5	6.2	81.3	(26.2-189.6)					
Female	4	2.2	nc	(nc-nc)	Female	18	18.8	95.6	(56.6-151.1)
Lung and Bronchus					All Sites / Types				
Male	63	46.2	136.3	(104.7-174.4)	Male	380	323.1	117.6	(106.1-130.1)
Female	66	45.0	146.7	(113.5-186.7)	Female	362	301.3	120.1	(108.1-133.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

	<u>Obs</u>	Exp	SIR	95% CI	min otaniaa aleoa molaonoo ka	Obs	<u>Ехр</u>	SIR	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	2	3.1	nc	(nc-nc)	Male	9	2.6	344.0	(157.0-653.1)
Female	0	0.9	nc	(nc-nc)	Female	6	2.1	287.9	(105.1-626.6)
Brain and Other Ner	vous Sys	<u>tem</u>			Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	15	14.8	101.4	(56.7-167.3)	Female	4	1.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	1	1.8	nc	(nc-nc)
Female	0	8.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	4	4.6	nc	(nc-nc)					
Female	8	3.2	247.6	(106.6-487.8)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	8.0	nc	(nc-nc)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	23	13.6	169.3	(107.3-254.1)
Female	0	0.3	nc	(nc-nc)					
Kidney & Renal Pelv	<u>/is</u>				<u>Stomach</u>				
Male	0	2.2	nc	(nc-nc)	Male	0	8.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	3	8.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Liver and Intrahepat	tic Bile Du				Uteri Corpus and Uterus,	NOS			
Male	0	1.1	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	5	3.2	157.8	(50.8-368.2)
Lung and Bronchus	<u>i</u>				All Sites / Types				
Male	1	5.9	nc	(nc-nc)	Male	53	49.3	107.6	(80.6-140.7)
Female	5	5.0	100.7	(32.4-234.9)	Female	53	44.3	119.7	(89.6-156.5)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

[•] Shading indicates the statistical significance of the SIR at 95% level of probability;

nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

	<u>Obs</u>	Exp	SIR	95% CI	Otaliaa aleea molaciio	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	7.8	90.2	(36.1-185.9)	Male	18	5.5	329.3	(195.0-520.4)
Female	0	2.3	nc	(nc-nc)	Female	8	4.0	202.5	(87.2-399.0)
Brain and Other Ner	rvous Sys	<u>tem</u>			Multiple Myeloma				
Male	1	1.8	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	8.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	1	0.2	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	46	30.2	152.2	(111.4-203.0)	Female	5	3.2	154.5	(49.8-360.5)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	2	3.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	9	10.5	85.5	(39.0-162.3)					
Female	5	8.0	62.5	(20.1-145.8)	Female	0	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	46	32.9	139.6	(102.2-186.2)
Female	0	0.5	nc	(nc-nc)					
Kidney & Renal Pelv	<u>vis</u>				<u>Stomach</u>				
Male	5	4.6	108.2	(34.9-252.6)	Male	1	1.9	nc	(nc-nc)
Female	5	2.2	222.3	(71.6-518.7)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	2.9	238.8	(95.7-492.0)	Male	2	1.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	8	5.4	147.3	(63.4-290.2)
Liver and Intrahepar	tic Bile Dι				Uteri Corpus and Uteri	ıs, NOS			
Male	5	2.5	203.4	(65.6-474.7)					
Female	0	0.6	nc	(nc-nc)	Female	6	6.7	89.6	(32.7-195.1)
Lung and Bronchus					All Sites / Types				
Male	4	14.8	nc	(nc-nc)	Male	125	112.9	110.7	(92.1-131.9)
Female	17	12.2	139.6	(81.3-223.5)	Female	117	95.3	122.8	(101.5-147.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

BoylstonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

Obs SIR 95% CI Obs SIR 95% CI Exp Exp Bladder, Urinary Melanoma of Skin 5 Male (36.5-264.5)3 3.0 4.4 113.3 Male nc (nc-nc) Female 1 1 2.3 1.5 nc (nc-nc) Female nc (nc-nc) **Brain and Other Nervous System Multiple Myeloma** 0 0.7 Male 1 0.9 nc (nc-nc) Male nc (nc-nc) 0 0 0.5 0.7 Female Female (nc-nc) (nc-nc) nc nc Non-Hodgkin Lymphoma **Breast** Male 0 0.1 (nc-nc) Male 0 2.6 (nc-nc) nc nc 23 17.0 135.3 Female 0 2.0 Female (85.8-203.1)(nc-nc) nc **Cervix Uteri** Oral Cavity & Pharynx 2.0 1 Male nc (nc-nc) 2 0.7 2 8.0 Female Female nc (nc-nc) nc (nc-nc) Colon / Rectum Ovary 2 Male 5.9 nc (nc-nc) 5 0 Female 4.9 102.1 (32.9-238.2)Female 1.6 nc (nc-nc) **Esophagus** Pancreas Pancreas 1 0 1.3 1.4 Male nc (nc-nc) Male nc (nc-nc) 0 0.3 Female 0 Female (nc-nc) 1.3 (nc-nc) nc nc **Prostate** Hodgkin Lymphoma Male 1 0.4 Male 26 18.3 141.7 (92.6-207.7) (nc-nc) nc

Stomach

Testis

Thyroid

All Sites / Types

Male

Male

Male

Female

Female

Male

Female

Uteri Corpus and Uterus, NOS

Female

2

0

2

2

6

3

64

52

1.1

0.5

0.6

1.0

3.0

3.8

63.0

55.8

nc

nc

nc

nc

nc

101.6

93.2

200.2

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(78.2-129.8)

(69.6-122.2)

(73.1-435.8)

•	Obs = observed	case count; Exp	= expected	case count;
---	----------------	-----------------	------------	-------------

SIR = standardized incidence ratio ((Obs / Exp) X 100);

0

3

2

1

0

2

0

0

6

6

0.3

2.5

1.3

0.7

0.2

1.6

1.1

1.3

0.4

8.4

7.6

nc

nc

nc

nc

nc

nc

nc

nc

nc

71.8

79.1

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(nc-nc)

(26.2-156.2)

(28.9-172.2)

Female

Male

Male

Male

Male

Male

Female

Female

Lung and Bronchus

Liver and Intrahepatic Bile Ducts

Female

Female

Female

Kidney & Renal Pelvis

Larynx

Leukemia

 ^{95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs 95% CI Obs Exp SIR 95% CI Exp SIR Bladder, Urinary Melanoma of Skin 44 98.3 (71.4-132.0)29 26.7 108.8 Male 44.8 Male (72.8-156.2)16 89.7 Female 17.8 (51.2-145.6)Female 31 21.4 145.0 (98.5-205.8)**Brain and Other Nervous System Multiple Myeloma** 9 113.9 7 6.9 100.8 Male 7.9 (52.0-216.3)Male (40.4-207.6)10 5 6.8 146.4 (70.1-269.3)Female 5.8 86.5 Female (27.9-201.8)Non-Hodgkin Lymphoma **Breast** 1 1.2 (nc-nc) Male 16 23.4 68.4 (39.1-111.1) Male nc 167 161.1 103.7 Female 21.9 Female (88.5-120.6)19 86.8 (52.3-135.6)**Cervix Uteri Oral Cavity & Pharynx** 15.9 100.5 Male 16 (57.4-163.3)4 6.1 5 8.1 61.8 Female Female (19.9-144.2)nc (nc-nc) Colon / Rectum Ovary Male 60 55.1 108.8 (83.1-140.1)69 131.7 Female 59.5 116.0 (90.2-146.8)Female 21 15.9 (81.5-201.3) **Esophagus Pancreas** 79.3 16 11.4 140.7 (80.4-228.5)11 13.9 (39.5-141.9)Male Male Female 62.7 Female 4 3.5 (nc-nc) 10 15.9 (30.0-115.3)nc **Hodgkin Lymphoma Prostate** 4 3.2 Male 168 161.5 104.0 (88.9-121.0) Male nc (nc-nc) 2 2.6 Female nc (nc-nc) Kidney & Renal Pelvis Stomach Male 22 21.8 100.8 (63.1-152.6)Male 16 10.5 151.9 (86.8-246.8)Female 11 13.7 80.1 (39.9-143.3)Female 10 6.8 147.2 (70.5-270.8)Larynx **Testis** 5 4 6.5 4.6 109.3 Male Male (35.2-255.1) nc (nc-nc) 3 Female 1.9 nc (nc-nc) **Leukemia Thyroid** 16 14.9 107.1 3 7.4 Male (61.2-173.9)Male (nc-nc) nc Female 10 12.1 82.8 (39.7-152.3)Female 24 23.9 100.5 (64.4-149.6)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 7 11.1 62.9 (25.2-129.7)1 4.3 Female nc (nc-nc) Female 36 36.6 98.3 (68.9-136.1) **Lung and Bronchus** All Sites / Types Male 89 81.6 109.1 598 574.6 104.1 (95.9-112.7)(87.6-134.2)Male Female 104 86.2 120.7 (98.6-146.2)Female 614 580.2 105.8 (97.6-114.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

	Obs	Exp	SIR	95% CI	, With Standardized incluence	Obs	-2000 <u>Exp</u>	SIR	95% CI
Bladder, Urinary	<u> </u>	<u>=~F</u>	<u> </u>	<u> </u>	Melanoma of Skin	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Male	14	20.8	67.2	(36.7-112.8)	Male	19	10.9	174.1	(104.8-271.9)
Female	7	7.2	97.1	(38.9-200.2)	Female	16	7.6	211.4	(120.8-343.3)
Brain and Other Ner				(,	Multiple Myeloma				(
Male	4	3.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>				,	Non-Hodgkin Lymphor				,
Male	0	0.5	nc	(nc-nc)	Male	9	9.8	91.4	(41.7-173.6)
Female	65	58.2	111.7	(86.2-142.3)	Female	8	8.5	94.4	(40.7-186.1)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	11	6.0	183.5	(91.5-328.3)
Female	1	2.0	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	19	24.5	77.7	(46.7-121.3)					
Female	18	24.3	74.0	(43.8-117.0)	Female	3	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	107.1	(34.5-249.9)	Male	6	6.2	97.3	(35.5-211.8)
Female	0	1.4	nc	(nc-nc)	Female	7	6.5	107.1	(42.9-220.6)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	3	1.0	nc	(nc-nc)	Male	88	63.8	138.0	(110.7-170.0)
Female	2	8.0	nc	(nc-nc)					
Kidney & Renal Pelv	<u>/is</u>				<u>Stomach</u>				
Male	6	8.7	69.0	(25.2-150.1)	Male	3	4.8	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	2.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	6	6.4	93.8	(34.2-204.1)	Male	1	2.5	nc	(nc-nc)
Female	6	4.6	129.4	(47.3-281.7)	Female	4	7.5	nc	(nc-nc)
Liver and Intrahepat					Uteri Corpus and Uteru	ıs, NOS			
Male	3	4.4	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)	Female	16	12.9	124.1	(70.9-201.5)
Lung and Bronchus	-			/=a = · · = =:	All Sites / Types	0.5.5		100 -	
Male	29	36.2	80.2	(53.7-115.2)	Male	250	241.0	103.7	(91.3-117.4)
Female	26	33.5	77.6	(50.7-113.7)	Female	207	218.2	94.9	(82.4-108.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

	Obs	<u>Ехр</u>	SIR	95% CI	with Standardized incidence	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary	<u> </u>	<u> </u>	<u> </u>	<u> </u>	Melanoma of Skin	<u></u>	<u> </u>	<u> </u>	<u> </u>
Male	22	19.5	112.7	(70.6-170.7)	Male	18	14.7	122.3	(72.5-193.3)
Female	8	6.9	116.8	(50.3-230.1)	Female	15	10.9	137.5	(76.9-226.9)
Brain and Other Nei				(,	Multiple Myeloma				(
Male	5	5.0	100.8	(32.5-235.3)	Male	3	3.4	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>				,	Non-Hodgkin Lymphor	na			, ,
Male	0	0.6	nc	(nc-nc)	Male	 12	12.6	95.3	(49.2-166.5)
Female	92	75.2	122.4	(98.6-150.1)	Female	10	9.2	108.8	(52.1-200.1)
Cervix Uteri				,	Oral Cavity & Pharynx				
					Male	8	9.3	86.4	(37.2-170.2)
Female	6	3.4	175.5	(64.1-381.9)	Female	6	3.6	167.4	(61.1-364.5)
Colon / Rectum					<u>Ovary</u>				
Male	24	26.6	90.2	(57.7-134.1)					
Female	26	23.0	112.9	(73.7-165.4)	Female	11	7.3	151.3	(75.4-270.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.7	105.8	(38.6-230.2)	Male	8	6.4	124.6	(53.6-245.5)
Female	3	1.3	nc	(nc-nc)	Female	7	6.0	115.8	(46.4-238.5)
Hodgkin Lymphoma	<u>a</u>				<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	82	80.3	102.1	(81.2-126.7)
Female	2	1.9	nc	(nc-nc)					
Kidney & Renal Pel	<u>vis</u>				<u>Stomach</u>				
Male	14	11.9	117.9	(64.4-197.8)	Male	3	4.9	nc	(nc-nc)
Female	5	6.0	83.3	(26.8-194.4)	Female	1	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	3.3	nc	(nc-nc)	Male	6	5.1	118.7	(43.3-258.4)
Female	0	0.8	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	8	7.8	102.7	(44.2-202.3)	Male	11	5.4	205.4	(102.4-367.5)
Female	1	5.3	nc	(nc-nc)	Female	17	14.3	118.5	(69.0-189.8)
Liver and Intrahepa	<u>tic Bile Dι</u>	<u>ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	7	6.1	114.4	(45.8-235.7)					
Female	1	1.7	nc	(nc-nc)	Female	20	16.8	118.8	(72.6-183.6)
Lung and Bronchus	='				All Sites / Types				
Male	44	37.0	119.0	(86.5-159.7)	Male	317	289.7	109.4	(97.7-122.1)
Female	50	34.5	144.8	(107.4-190.9)	Female	305	256.2	119.0	(106.1-133.2)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI		<u>Obs</u>	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	3.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>em</u>			Multiple Myeloma				
Male	1	8.0	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	10	13.5	74.0	(35.4-136.0)	Female	2	1.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	1.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	3	5.0	nc	(nc-nc)					
Female	8	4.1	194.7	(83.8-383.6)	Female	0	1.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	15.0	73.4	(36.6-131.4)
Female	2	0.3	nc	(nc-nc)					
Kidney & Renal Pelv	<u>ris</u>				<u>Stomach</u>				
Male	4	2.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Liver and Intrahepat	ic Bile Du	<u>cts</u>			Uteri Corpus and Uterus,	NOS			
Male	1	1.1	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	5	7.0	71.4	(23.0-166.7)	Male	43	52.6	81.7	(59.1-110.1)
Female	11	6.0	184.8	(92.1-330.7)	Female	54	44.9	120.2	(90.3-156.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

	Obs	Exp	SIR	95% CI	with Standardized incluent	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary				<u></u>	Melanoma of Skin				<u> </u>
Male	89	84.9	104.8	(84.2-129.0)	Male	43	56.5	76.1	(55.1-102.5)
Female	22	33.5	65.6	(41.1-99.3)	Female	34	49.5	68.7	(47.6-96.0)
Brain and Other N	ervous Sy	<u>stem</u>			Multiple Myeloma				
Male	11	18.6	59.0	(29.4-105.6)	Male	19	13.8	137.9	(83.0-215.3)
Female	8	16.1	49.7	(21.4-97.9)	Female	15	11.0	136.3	(76.2-224.8)
<u>Breast</u>					Non-Hodgkin Lymph	<u>ioma</u>			
Male	2	2.4	nc	(nc-nc)	Male	44	49.3	89.3	(64.9-119.9)
Female	306	344.1	88.9	(79.2-99.5)	Female	60	43.7	137.2	(104.7-176.6)
Cervix Uteri					Oral Cavity & Pharyr	<u>ıx</u>			
					Male	36	34.5	104.4	(73.1-144.6)
Female	32	15.3	209.4	(143.2-295.6)	Female	13	16.8	77.4	(41.2-132.3)
Colon / Rectum					<u>Ovary</u>				
Male	112	109.4	102.4	(84.3-123.2)					
Female	133	113.4	117.3	(98.2-139.0)	Female	37	33.6	110.2	(77.6-151.8)
Esophagus					<u>Pancreas</u>				
Male	40	22.8	175.5	(125.4-239.0)	Male	25	27.0	92.7	(60.0-136.8)
Female	9	6.5	139.1	(63.5-264.1)	Female	29	29.8	97.5	(65.3-140.0)
Hodgkin Lymphon	<u>na</u>				<u>Prostate</u>				
Male	6	9.2	65.2	(23.8-141.9)	Male	278	325.1	85.5	(75.7-96.2)
Female	9	7.7	117.3	(53.5-222.6)					
Kidney & Renal Pe	<u>elvis</u>				<u>Stomach</u>				
Male	50	45.8	109.3	(81.1-144.1)	Male	23	20.6	111.9	(70.9-167.8)
Female	35	28.1	124.7	(86.8-173.4)	Female	18	12.7	141.2	(83.6-223.2)
<u>Larynx</u>					<u>Testis</u>				
Male	19	13.1	144.7	(87.1-226.0)	Male	13	14.9	87.5	(46.6-149.7)
Female	3	3.9	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	24	32.0	74.9	(48.0-111.5)	Male	14	18.1	77.2	(42.2-129.5)
Female	17	25.6	66.3	(38.6-106.2)	Female	72	62.6	115.1	(90.0-144.9)
Liver and Intrahep	atic Bile D				Uteri Corpus and Ute	erus, NOS			
Male	26	23.3	111.4	(72.8-163.3)					
Female	9	8.4	107.2	(48.9-203.5)	Female	68	77.2	88.1	(68.4-111.7)
Lung and Bronchu	·				All Sites / Types				
Male	189	156.9	120.5	(103.9-139.0)	Male	1158	1167.5	99.2	(93.6-105.1)
Female	179	164.7	108.7	(93.3-125.8)	Female	1219	1199.7	101.6	(96.0-107.5)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

	<u>Obs</u>	Exp	SIR	95% CI	min otaniaa aleoa molaonoo ka	Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	3.5	170.6	(62.3-371.4)	Male	0	2.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Brain and Other Ner	vous Syst	<u>em</u>			Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	1	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	15	12.7	118.5	(66.3-195.4)	Female	1	1.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	1	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	2	4.5	nc	(nc-nc)					
Female	5	4.0	126.1	(40.6-294.2)	Female	2	1.2	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Hodgkin Lymphoma	<u>l</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	13.2	83.1	(41.4-148.7)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelv	<u>ris</u>				<u>Stomach</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	8.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Liver and Intrahepat	ic Bile Du	<u>cts</u>			Uteri Corpus and Uterus,	<u>NOS</u>			
Male	0	1.0	nc	(nc-nc)					
Female	1	0.3	nc	(nc-nc)	Female	6	2.9	206.1	(75.3-448.6)
Lung and Bronchus					All Sites / Types				
Male	8	6.5	122.9	(52.9-242.2)	Male	42	47.2	89.0	(64.1-120.3)
Female	11	6.2	178.7	(89.1-319.8)	Female	53	43.1	122.9	(92.1-160.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

	Obs	Exp	SELVED AND EX	95% CI	with Standardized incluence	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinary	<u> </u>	<u> </u>	<u> </u>	<u> </u>	Melanoma of Skin	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Male	49	53.4	91.8	(67.9-121.3)	Male	57	34.6	164.7	(124.7-213.4)
Female	17	22.4	75.8	(44.1-121.4)	Female	68	32.6	208.3	(161.7-264.1)
Brain and Other N				(,	Multiple Myeloma				(
Male	18	10.7	168.6	(99.9-266.4)	Male	5	8.6	58.4	(18.8-136.2)
Female	13	9.9	131.8	(70.1-225.5)	Female	10	7.3	136.2	(65.2-250.5)
<u>Breast</u>				,	Non-Hodgkin Lymphor				,
Male	0	1.5	nc	(nc-nc)	Male	36	30.1	119.7	(83.8-165.7)
Female	251	220.1	114.1	(100.4-129.1)	Female	29	28.8	100.6	(67.3-144.4)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	16	20.8	77.0	(44.0-125.0)
Female	6	9.9	60.5	(22.1-131.7)	Female	10	11.0	90.5	(43.3-166.5)
Colon / Rectum					<u>Ovary</u>				
Male	58	68.3	84.9	(64.5-109.8)					
Female	69	77.9	88.6	(68.9-112.1)	Female	22	21.8	100.9	(63.2-152.8)
Esophagus					<u>Pancreas</u>				
Male	10	13.9	71.8	(34.4-132.1)	Male	23	16.8	137.2	(86.9-205.8)
Female	6	4.3	140.3	(51.2-305.3)	Female	19	20.2	94.1	(56.6-147.0)
Hodgkin Lymphon	<u>na</u>				<u>Prostate</u>				
Male	4	5.5	nc	(nc-nc)	Male	212	196.5	107.9	(93.9-123.4)
Female	6	5.0	119.3	(43.6-259.7)					
Kidney & Renal Pe	<u>elvis</u>				<u>Stomach</u>				
Male	27	27.6	97.9	(64.5-142.5)	Male	9	12.9	70.0	(31.9-132.9)
Female	16	17.9	89.4	(51.1-145.2)	Female	6	8.9	67.5	(24.6-146.9)
<u>Larynx</u>					<u>Testis</u>				
Male	6	8.0	75.1	(27.4-163.4)	Male	13	9.3	139.6	(74.3-238.7)
Female	0	2.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	33	19.1	173.1	(119.1-243.1)	Male	27	10.8	249.5	(164.4-363.1)
Female	16	16.3	98.0	(56.0-159.2)	Female	60	40.4	148.6	(113.4-191.3)
Liver and Intrahep	atic Bile D	<u>)ucts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	6	14.2	42.1	(15.4-91.7)					
Female	4	5.6	nc	(nc-nc)	Female	50	48.8	102.5	(76.0-135.1)
Lung and Bronchu					All Sites / Types				
Male	65	96.7	67.2	(51.9-85.6)	Male	713	714.8	99.7	(92.6-107.3)
Female	84	106.0	79.2	(63.2-98.1)	Female	824	781.7	105.4	(98.3-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

	<u>Obs</u>	Exp	SIR	95% CI	nii otaliaa aleea molaonoo nast	Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	2.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	8.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Brain and Other Nerv	ous Syste	<u>m</u>			Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	9	8.3	108.6	(49.5-206.1)	Female	1	1.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	3	3.1	nc	(nc-nc)					
Female	2	2.6	nc	(nc-nc)	Female	1	8.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	8.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	9.2	75.9	(30.4-156.4)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis	<u>s</u>				<u>Stomach</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	8.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Liver and Intrahepation	Bile Duc				Uteri Corpus and Uterus, N	NOS			
Male	1	0.7	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	4.4	nc	(nc-nc)	Male	28	32.5	86.3	(57.3-124.7)
Female	4	3.8	nc	(nc-nc)	Female	24	27.9	85.9	(55.0-127.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	, min Gundaraizoa moidono.	<u>Obs</u>	<u>Exp</u>	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	28	25.0	112.0	(74.4-161.9)	Male	21	16.7	125.9	(77.9-192.5)
Female	10	9.0	111.4	(53.3-204.8)	Female	18	12.7	141.3	(83.7-223.4)
Brain and Other Ner	vous Sys	<u>tem</u>			Multiple Myeloma				
Male	8	5.2	154.9	(66.7-305.2)	Male	8	4.1	193.3	(83.2-381.0)
Female	3	4.1	nc	(nc-nc)	Female	5	3.0	168.9	(54.4-394.2)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	1	0.7	nc	(nc-nc)	Male	19	14.2	133.9	(80.6-209.1)
Female	102	96.0	106.2	(86.6-128.9)	Female	13	11.6	112.0	(59.6-191.6)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	4	10.5	nc	(nc-nc)
Female	5	3.9	126.9	(40.9-296.1)	Female	8	4.6	173.9	(74.9-342.7)
Colon / Rectum					<u>Ovary</u>				
Male	27	32.4	83.3	(54.9-121.3)					
Female	36	29.0	124.1	(86.9-171.7)	Female	5	9.2	54.1	(17.4-126.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.1	70.5	(22.7-164.5)	Male	9	8.1	111.7	(51.0-212.1)
Female	3	1.7	nc	(nc-nc)	Female	7	7.8	89.3	(35.8-184.0)
Hodgkin Lymphoma	<u>1</u>				<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	102	105.3	96.9	(79.0-117.6)
Female	3	1.7	nc	(nc-nc)					
Kidney & Renal Pelv	<u>/is</u>				<u>Stomach</u>				
Male	12	13.9	86.4	(44.6-151.0)	Male	6	6.0	99.5	(36.3-216.6)
Female	8	7.8	102.2	(44.0-201.4)	Female	5	3.2	156.3	(50.4-364.8)
<u>Larynx</u>					<u>Testis</u>				
Male	1	4.1	nc	(nc-nc)	Male	6	3.6	167.4	(61.1-364.4)
Female	0	1.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	14	8.9	158.2	(86.4-265.4)	Male	4	5.2	nc	(nc-nc)
Female	5	6.4	78.0	(25.1-182.0)	Female	17	16.1	105.5	(61.4-168.9)
Liver and Intrahepa	tic Bile Du	<u>icts</u>			Uteri Corpus and Uteru	ıs, NOS			
Male	9	7.1	126.4	(57.7-239.9)					
Female	1	2.2	nc	(nc-nc)	Female	26	22.7	114.6	(74.9-168.0)
Lung and Bronchus	<u>i</u>				All Sites / Types				
Male	58	48.0	120.9	(91.8-156.3)	Male	368	353.6	104.1	(93.7-115.3)
Female	49	46.6	105.3	(77.9-139.2)	Female	375	325.0	115.4	(104.0-127.7)

[•] Obs = observed case count; Exp = expected case count;

SIR = standardized incidence ratio ((Obs / Exp) X 100);

^{• 95%} CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

Shading indicates the statistical significance of the SIR at 95% level of probability;

[•] nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008 Obs SIR 95% CI Exp SIR 95% CI Exp Obs Bladder, Urinary Melanoma of Skin 42 56.4 74.5 (40.6-76.2)44 51.9 84.7 (61.6-113.7)Male Male 21 69.6 Female 30.2 (43.0-106.3)Female 53 49.2 107.7 (80.7-140.9)**Brain and Other Nervous System Multiple Myeloma** 16 92.8 12.1 107.6 Male 17.2 (53.0-150.7)Male 13 (57.3-184.1) 12 80.6 Female 14.9 (41.6-140.8)Female 10 9.9 100.5 (48.1-184.9)Non-Hodgkin Lymphoma **Breast** 0 2.1 (nc-nc) Male 49 45.1 108.8 (80.5-143.8)Male nc 315 315.6 99.8 Female Female (89.1-111.5)28 40.3 69.5 (46.2-100.5)**Cervix Uteri Oral Cavity & Pharynx** 25 30.5 82.1 Male (53.1-121.2)9 15.4 58.5 14 15.7 89.3 Female (26.7-111.0)Female (48.8-149.9)Colon / Rectum Ovary Male 95 96.4 98.5 (79.7-120.5)93 103.0 90.3 Female (72.8-110.6)Female 31 31.2 99.3 (67.5-141.0) **Esophagus Pancreas** 40.3 59.4 8 23.6 (32.4-99.6)19.8 (17.4-79.5)14 Male Male 4 59.8 Female 5.8 nc (nc-nc) Female 16 26.8 (34.2-97.1)**Hodgkin Lymphoma Prostate** 9 11.4 78.9 (36.0-149.8)276 278.4 99.1 (87.8-111.6) Male Male 6 Female 8.8 67.8 (24.8-147.7)Kidney & Renal Pelvis Stomach 66.9 Male 27 40.4 (44.1-97.3)Male 20 18.2 110.0 (67.2-169.9)Female 16 25.6 62.6 (35.7-101.6)Female 14 11.5 121.2 (66.2-203.4)Larynx **Testis** 9 79.3 11.4 (36.2-150.5)20.4 83.3 Male Male 17 (48.5-133.4)2 Female 3.5 (nc-nc) nc **Leukemia Thyroid** 15 28.7 52.3 (29.2-86.2)24 18.1 132.6 (84.9-197.3)Male Male Female 25 23.0 108.9 (70.5-160.8)Female 77 64.6 119.2 (94.1-149.0) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 28 20.5 136.4 (90.6-197.2)12 Female 7.6 157.5 (81.3-275.1)Female 76 70.4 107.9 (85.0-135.1) **Lung and Bronchus** All Sites / Types 82.1 Male 112 136.4 (67.6-98.8)913 1038.1 87.9 (82.3-93.8)Male

• Obs = observed case count; Exp = expected case count;

147.9

Female

103

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(56.9-84.5)

Shading indicates the statistical significance of the SIR at 95% level of probability;

69.7

• nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

1011

1108.0

91.2

(85.7-97.0)

Canton

	Obs	Exp	SIR	95% CI	with Standardized incluence	Obs	-2000 <u>Exp</u>	SIR	95% CI
Bladder, Urinary		<u> </u>		<u></u>	Melanoma of Skin				
Male	17	27.1	62.8	(36.6-100.6)	Male	14	16.5	85.1	(46.5-142.7)
Female	14	10.9	128.5	(70.2-215.6)	Female	4	13.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	4.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	9	3.5	254.7	(116.2-483.5)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.8	nc	(nc-nc)	Male	9	14.4	62.5	(28.5-118.6)
Female	88	98.4	89.5	(71.7-110.2)	Female	15	13.4	111.8	(62.5-184.5)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	6	9.9	60.5	(22.1-131.7)
Female	1	3.8	nc	(nc-nc)	Female	9	4.9	182.3	(83.2-346.0)
Colon / Rectum					<u>Ovary</u>				
Male	45	33.9	132.6	(96.7-177.4)					
Female	34	37.3	91.2	(63.1-127.4)	Female	4	9.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.9	131.2	(59.9-249.0)	Male	10	8.4	118.8	(56.9-218.6)
Female	0	2.1	nc	(nc-nc)	Female	7	9.8	71.2	(28.5-146.7)
Hodgkin Lymphoma					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	87	97.2	89.6	(71.7-110.5)
Female	1	1.6	nc	(nc-nc)					
Kidney & Renal Pelvis					<u>Stomach</u>				
Male	8	13.4	59.9	(25.8-118.0)	Male	6	6.4	93.3	(34.1-203.1)
Female	12	8.3	145.0	(74.8-253.3)	Female	2	4.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	5	3.9	127.0	(40.9-296.4)	Male	2	2.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	9	9.2	97.3	(44.4-184.8)	Male	4	4.7	nc	(nc-nc)
Female	3	7.5	nc	(nc-nc)	Female	20	14.9	133.9	(81.8-206.8)
Liver and Intrahepatic Bile Ducts					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.9	87.3	(31.9-190.0)					
Female	0	2.6	nc	(nc-nc)	Female	19	21.8	87.0	(52.4-135.9)
Lung and Bronchus					All Sites / Types				
Male	48	48.8	98.4	(72.5-130.5)	Male	334	349.6	95.5	(85.6-106.3)
Female	60	51.2	117.1	(89.4-150.8)	Female	335	355.0	94.4	(84.5-105.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;